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Abstract
Cellular division is primarily controlled at the G1 to S-phase transition of the cell cycle by
the retinoblastoma tumor-suppressor protein (pRB). The ability of pRB to restrict S-phase
entry is primarily attributed to the repression of E2F transcription factors required to
upregulate cell cycle target genes necessary for cellular division. Interestingly, while pRB is
disrupted in the vast majority of human cancers, mutations typically target upstream
regulators of pRB leading to inactivation through hyperphosphorylation. The rarity of direct
pRB mutations suggests that the regulation of the cell cycle by pRB may involve additional
mechanisms outside of E2F repression, as this could to be eliminated via point mutations.
Indeed, the Rb1G/G mouse model developed by Cecchini et al., which lacks the ability to form
pRB-E2F complexes, showed minimal phenotypic alterations. As described in chapter 2,
pRB can stabilize p27 in the absence of pRB-E2F interaction, maintaining cell cycle control.
Importantly, the loss of pRB-E2F interactions in addition to the loss of p27 leads to a
defective DNA damage response, and ultimately pituitary tumor development. The minimal
region of pRB necessary to elicit a cell cycle arrest is the pRB large pocket which contains 3
distinct binding surfaces. Using synthetic mutants of pRB we show that all three of these
sites play a role in regulating the cell cycle both in vitro and in vivo. Finally, to understand
E2F independent pRB-mediated tumor-suppression, Rb1G/G mice were intercrossed with
mice harboring oncogenic KrasG12D, or deletions of p21 or p53. While KrasG12D expressioninduced tumorigenesis was not further affected by the Rb1G mutation, the phenotype of p53
null animals was exacerbated by the Rb1G mutation. Interestingly, the loss of p21 in Rb1G/G
mice showed no tumor development despite the overlapping function with p27. While it is
unclear why there is a discrepancy in phenotype between Rb1G/G mice lacking p21 and those
lacking p27, p27 has non-canonical functions which may be contributing to tumor
development. Taken together this work describes E2F independent functions of pRB in cell
cycle control and tumor suppression and provides a rationale for the unusual disruption of
pRB in human cancers by hyperphosphorylation.
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Chapter 1

1

Introduction
1.1

Overview

Cancer can be characterized as an overall loss of homeostasis in a multicellular
organism resulting in aberrant growth and the development of a tumor 1. Over the years,
several pathways have been described as playing critical roles in carcinogenesis 1. Several
factors work together to bring about this phenotype, ranging from the ability to proliferate
independent of growth signals, to bypassing fail-safe mechanisms designed to inhibit cell
growth or initiate programmed cell death in response to aberrant cell growth 1. Therefore,
the mechanisms that are involved in regulating cell cycle control are often targets of
cancer causing mutations1. Once mutations arise in these critical pathways the affected
cell is then capable of bypassing the various tumor suppressive functions and divide
uncontrollably resulting in tumor formation. As such, cellular proliferation is a key
component of cancer development and progression. Understanding the mechanisms that
control proliferation is critical to the development of novel targeted therapies that aim to
re-establish proliferative control in cancer cells.

1.2

Cellular division

The process through which cells proliferate is known as the cell division cycle 2. The
cycle is split into 4 main phases separated by 3 checkpoints to regulate the transitions
between them (Figure 1.1)3,4. Cellular division is tightly regulated in the body to ensure
that various tissues are sustained at appropriate sizes, and vital structures are maintained 5.

2

Figure 1.1: Depiction of the mammalian cell cycle.
The 4 phases of the cell cycle are indicated: Gap 1 (G1), Synthesis (S), Gap 2 (G2), and
Mitosis (M). Also indicated are the 3 main checkpoints that regulate cell cycle
progression at various stages. The restriction point controls the transition between G1 and
S-phase ensuring appropriate proliferation. The DNA damage checkpoint occurs in G2
and ensures the DNA is intact prior to Mitosis. Finally, the spindle assemble checkpoint
confirms that each chromosome pair is attached to both spindle poles prior to cytokinesis.

3

As such, several pathways including but not limited to, growth factors, cell to cell
contacts and mitogen availability are all important to controlling cellular division 6-8. Due
to the critical involvement of cellular proliferation in carcinogenesis all cancer cells must
bypass these growth regulatory pathways1,6,8. While normal cells without appropriate
signals will not enter the cell cycle, the acquisition of mutations in critical tumorsuppressive or oncogenic pathways can lead to the re-entry of these cells into the cell
cycle and potentially lead to tumor development 1,9.
Given the possibility of cancer developing due to a defective cell division cycle,
cellular proliferation is tightly controlled to ensure that 2 daughter cells are faithfully
produced and only when it is appropriate to do so. For actively cycling normal cells, the
first phase of the cell cycle known as Gap 1 phase (G1) in which the cell, through a series
of growth signalling pathways, determines if conditions are appropriate to initiate cell
cycle progression10,11. Additionally, in this phase the cell physically grows and produces
a variety of proteins that are needed for DNA replication12. Once appropriate conditions
are met for cell cycle entry, the cell then transitions into the synthesis-phase also known
as S-phase in which DNA is replicated13. To ensure that the DNA is only replicated once
per division it is critical that once a cell has begun to replicate its DNA that the cell cycle
is completed and cells do not revert to an earlier phase 14-16. Therefore, given the
importance of the G1-S transition phase boundary, it is understandable that this transition
is tightly regulated and known as the restriction point and the first major checkpoint in
the eukaryotic cell cycle (Figure 1.1)15,16.
In late G1 phase, a variety of proteins which are needed for DNA replication are
transcribed and translated17. These include a number of kinases, transcription factors, as
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well as replication fork components17. The prereplication complexes are then loaded on
the chromatin at origins of replications18. Following activation by S-phase kinases these
proteins can then unwind the DNA and begin the process of replicating the genome 18.
Since prereplication complexes can only be loaded in G1 this ensures that DNA is only
copied once per cell cycle18. Once the genome is fully replicated, the cell is then said to
be in the Gap 2 phase of the cell cycle or G2. Again, in this phase more proteins and
lipids are made in preparation for mitosis. In addition, the G2 phase of the cell cycle also
contains a DNA damage checkpoint in which the cell ensures that the genome is intact
and fully replicated prior to entry into mitosis (Figure 1.1)19.
During the fourth phase of cell division, mitosis (M-phase), the genome condenses
greatly, the nuclear envelop disintegrates, and the duplicated sister chromatids are aligned
in the center of the cell at the metaphase plate20. The final checkpoint of the cell cycle
then ensures that each pair of sister chromatids are bound by a spindle emanating from
the centrioles on either side of the cell21. Once this is confirmed the sister chromatids are
separated and one set is pulled towards each pole located at the periphery of the cell 21.
The cell then pinches in the middle leading to cleavage and the creation of two daughter
cells in the G1 phase of the cell cycle through a process known as cytokinesis 22. While
there are 3 main checkpoints in the cell cycle, the G1 restriction point is unique in the
ability to determine whether the cell divides or not 12,14,19,21. The remaining two
checkpoints, the G2 DNA damage checkpoint and the spindle assembly checkpoint, are
only able to stall the cell cycle and once the problems are corrected the cell then resumes
the cell division cycle (Figure 1.1)19,21.
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As the G1 to S-phase transition is unique in its ability to determine if the cell will
divide or remain quiescent, the pathways involved in this transition are highly
regulated8,14. Moreover, with the importance of this restriction point in regulating the
proliferation of cells it is often targeted by mutation in human cancers 1. There are several
proteins which help to regulate this critical restriction point of the cell cycle 8,10. These
proteins translate intra- and intercellular signals that ultimately influence the activity of
two protein families which work in opposition to one another 23. The branch which
promotes cell cycle entry is a group of kinases known as Cyclin dependent kinases
(CDKs)23. In contrast, a second group known as Cyclin dependent kinase inhibitors
(CKIs) works to prevent cell cycle advancement through direct interaction with CDKs,
inhibiting their activity23. Ultimately, these two sets of proteins determine the activity of
one of the key regulators of the G1-S transition, the retinoblastoma tumor suppressor
protein (pRB)24. The interactions between CDKs, CKIs, and pRB and how they influence
one another in the context of cell cycle control is the focus of this thesis.

1.3
Identification of the retinoblastoma susceptibility
gene
The retinoblastoma tumor suppressor gene was first predicted through the study of the
childhood eye cancer, retinoblastoma25. Retinoblastoma presents in two different forms,
either unilateral, occurring in one eye, or bilateral, occurring in both eyes 25. In 1971,
Alfred Knudsen discovered that those children developing bilateral retinoblastoma
typically had a family history of the disease25. These children also developed cancer far
earlier than those developing unilateral cancer, which occurred later and typically had no
family history of retinoblastoma25. From this study Knudsen suggested his 2 hit
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hypothesis, which states that the development of retinoblastoma requires the loss or
mutation of both copies of a retinoblastoma susceptibility gene 25. This description of the
retinoblastoma susceptibility gene is the first example of a tumor suppressor protein,
which has since gone on to describe several proteins involved in the maintenance of
cellular homeostasis and the prevention of tumorigenesis.

1.4

Cloning of the RB1 gene.

The susceptibility factor associated with retinoblastoma development predicted by
Knudsen in 1971 was eventually found to be contained within a region on the q arm of
chromosome 1326. In 1986 two independent groups cloned this retinoblastoma
susceptibility gene referred to as the retinoblastoma gene (RB1)27,28. Consistent with
Knudsen’s hypothesis, patients with heritable forms of retinoblastoma were found to have
mutations in one copy of this gene throughout their body29. A second genetic event then
occurs somatically in the retina leading to the development of retinoblastoma in children.
This confirmed Knudsen’s two hit hypothesis and identified the first tumor suppressor
gene.
This disruption of the RB1 gene while critical for the development of retinoblastoma
started to be seen in other cancers26,30,31. First, those patients who survive retinoblastoma
as children have a likelihood of developing osteosarcoma far greater than that of the
general population26. Furthermore, these cancers also displayed the loss of heterozygosity
(LOH) or loss of the wild-type allele of the RB1 gene similar to the development of
retinoblastoma26. Additionally, direct RB1 mutation has also been identified in a large
majority of small cell lung cancers (SCLC) and a sizable proportion of breast cancers 30,31.
However, typically mutations in the pRB pathway occur upstream of pRB resulting in the
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hyperphosphorylation of pRB leading to its functional inactivation 30. Two of the most
common pathway mutations are deletion of p16 or amplification of Cyclin D both of
which lead to constitutive pRB hyperphosphorylation, inhibiting its various functions 30
The repercussions of functional disruption of pRB will be discussed later on. The
prevalence of pRB pathway disruption through direct or indirect mutation in cancers from
various disease sites suggests that the retinoblastoma gene product (pRB) encoded by the
RB1 gene is important in some vital cellular process which cells must bypass to become
tumorigenic.

1.5

pRB and viral oncoproteins

Shortly after cloning the RB1 gene, pRB was shown to directly interact with a variety
of viral oncoproteins including HPV-E7, SV-40 Large T antigen and Adenovirus E1A 3234

. As their name suggests, these viral oncoproteins can transform cells leading to

tumorigenesis35. Unsurprisingly then, when expressed these viral oncoproteins cause cells
to re-enter the cell cycle regardless of the presence or absence of growth factors 35.
Importantly, the association between pRB and viral oncoproteins leads to a disruption of
pRB function either through the degradation or sequestration of pRB molecules 36. Given
the importance of pRB in tumor suppression both in retinoblastoma as well as a large
variety of other cancers, and the fact that disruption of pRB function by viral
oncoproteins is coincident with cellular proliferation, it was suggested that pRB had a
role in the regulation of cell cycle progression 32-35 Finally, this role is likely ubiquitous as
the regulation of the cell cycle is important in all cells and not just the tumor cells in
which they are mutated.
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1.6

pRB-family proteins

The pRB family of proteins which consists of pRB, p107, and p130, are collectively
known as the pocket proteins as they all contain the characteristic pocket domain 37-39.
Furthermore, these were all identified through their ability to interact with the viral
oncoproteins E1A, E7 and SV-40 T antegin39-41. The characteristic pocket domain is
formed from two cyclin folds in the A and B domains of these proteins and facilitates the
association between the pocket protein and the E2 promoter binding factor (E2F)
transcription factors (Figure 1.2)42. While all three proteins contain this structure, p107
and p130 are more similar to each other in terms of sequence and have slightly different
pocket domains compared to pRB37. In particular, p107 and p130 contain an insertion
into the B domain of the pocket which may have implications in regulating their specific
binding partners (Figure 1.2)37. Pocket proteins lack DNA binding ability and therefore
must be recruited onto DNA by the various E2Fs with which they associate 43. This means
that chromatin localization relies not on the pocket protein itself but rather the consensus
sequence of the E2F transcription factors. Furthermore, in addition to binding to E2F
transcription factors, pocket proteins can also act as a scaffold to bring much larger
complexes to specific locations on the DNA which can further repress transcription 44.

1.7

Regulation of pocket proteins

The ability of the pocket proteins to influence E2F transcription factors is regulated
by two independent factors, expression and phosphorylation status. In general, the
expression of p107 and p130 fluctuate throughout the cell cycle with p130 being
expressed at high levels in quiescence, or G0 of the cell cycle and diminishing as the cell
progresses through G1 and S37. p107 by contrast, is most highly expressed in S-phase as
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Figure 1.2: Domain structure and interaction surfaces of pocket proteins.
(A) The A, B, and the C-terminal domains are shown for all 3 pocket proteins. The large
pocket is denoted by the red line and the small pocket is identified by the green line. (B)
The three large pocket interaction sites in pRB are shown. These are the E2F general
interaction facilitated by the entire large pocket, the LxCxE binding cleft located in the B
region of the pocket and the E2F1 specific interaction site which associates with pRB
through an interaction site in the C-terminus.
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it is a target of E2F dependent transcription37. pRB, on the other hand remains relatively
stable throughout the cell cycle with a slight increase in expression in S-phase due to E2F
dependent transcription37. The relative stability of pRB expression throughout the cell
cycle indicates that control of its function is largely independent of transcription and is
controlled instead by post-translational modifications, in particular phosphorylation 45.
Phosphorylation of pRB as well as the other pocket proteins is largely carried out by
Cyclin/CDK complexes45,46. Once a cell is stimulated to divide there is an increase in the
activity of Cyclin/CDK complexes leading to the phosphorylation of pRB disrupting
various interactions due to conformational changes 45,46.

1.8

Structure of pRB

The retinoblastoma gene product (pRB) is a globular protein which contains several
interacting domains which together regulate numerous cellular proteins influencing the
cell cycle45,47. The majority of these characterized domains are located in the C-terminal
two thirds of the protein which is referred to as the large pocket (Figure 1.2A)47. The
large pocket itself is made up of 3 main structures, the A and B domains each comprise of
cyclin folds which are joined together with a spacer creating the small pocket (Figure
1.2A)42. The large pocket is made up of this small pocket and the unstructured C-terminal
domain47. This thesis focuses on three independent binding interactions located in the
large pocket of pRB. These interactions are known as the general E2F binding site, the
LxCxE binding cleft and the E2F1 specific binding site (Figure 1.2B)42,45,48.

11

1.9

pRB-E2F interactions

First, and most well known of the various pRB interactors are the E2F transcription
factors43. This interaction is facilitated through the pocket domain of pRB and is involved
in pRB-mediated regulation of the cell cycle43. The importance of pRB-E2F regulation in
the cell cycle was initially identified through the use of Saos-2 arrest assays 49,50. In these
early experiments, it was shown that the minimal interacting domain necessary for pRBE2F association was also able to initiate a cell cycle arrest when expressed in Saos-2
cells49,50. Given this correlation, it is logical to assume that pRB-E2F interaction is
critical to regulation of the restriction point49,50. However, as shown in Figure 1.2, the
minimal domain required for pRB-E2F interaction, the large pocket, also contains a least
two other binding surfaces, the LxCxE binding cleft and the C-terminal E2F1 specific
interaction site (Figure 1.2B)42,50,51. This suggests that the ability of pRB to regulate the
cell cycle may be dependent on several interactions not just pRB binding to E2Fs.

1.10

Disruption of pRB by viral oncoproteins

Of particular note both viral oncoproteins, HPV-E7 and Adenovirus E1A have
multiple domains that are required for the effective association and inactivation of pRB
as well as their ability to transform cells 52,53. HPV-E7 eliminates pRB function by
targeting the protein for degradation53. As such, HPV-E7 requires both the CR2 domain
which contains the LxCxE motif to associate with pRB, as well as the CR1 domain which
recruits additional factors targeting the protein for degradation 35,53. Additionally, the Cterminus of HPV-E7 contains a low affinity pRB binding domain which is thought to
interact with the pRB-E2F binding pocket preventing E2F binding35. By contrast, E1A
eliminates pRB function through sequestration of pRB preventing it from functioning
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properly53. E1A contains two binding domains that are essential to oncogenic
transformation52. The CR1 domain mimics the transactivation domain of E2F and binds
in the pocket of pRB, this however is not sufficient to transform cells 52. The CR2 domain
of E1A contains the LxCxE domain which also allows for association between pRB and
E1A, however, once again this is not sufficient to allow for oncogenic transformation 52.
The requirement for disruption of both the pocket domain and the LxCxE binding domain
to successfully sequester pRB was some of the first evidence that pRB-E2F interactions
are not solely responsible for the tumor suppressive abilities of pRB. Presented in this
thesis are experiments which attempt to further explore the various functions of pRB
outside of the dogma of pRB repressing E2F dependent transcription.

1.11 E2F transcription factors as regulators of the cell
cycle
The E2F proteins are a family of transcription factors which bind to a variety of target
gene promoters to influence transcription necessary for regulating cell cycle entry54. This
family can be further divided into transcriptional activators (E2F1-3) and transcriptional
repressors (E2F4-5)54. Finally, there are three atypical E2Fs, (E2F6-8) whose function is
currently being explored, but are generally thought to be repressive and function
independently of pocket proteins55. Together with their dimerization partner,
Differentiation related transcription factor-1 polypeptide-1 (DP1) the activator E2Fs form
a heterodimer which binds to promoters of genes involved in DNA synthesis and cell
cycle progression54. Critically, activator E2Fs (E2F1-3) have been shown to be necessary
to allow for cellular division56. This function of E2F transcription factors is facilitated
through the transactivation domain located in the C-terminus of the activator E2Fs 54. This
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domain is responsible for recruiting transcriptional co-activators such as p300 leading to
the upregulation of genes important for S-phase progression 43. Importantly, in cells
stimulated to enter the cell cycle, E2F target genes are greatly upregulated coincident
with S-phase entry and DNA synthesis43. To prevent aberrant cell cycle entry, pRB
regulates E2F-mediated transcription through the pRB pocket domain 45. pRB is unique
among pocket proteins for its ability to bind to activator E2Fs (E2F1-3), in addition to the
repressor E2F443,57. By contrast p107 and p130 both only associate with the repressive
E2Fs (E2F4-5)43. This pocket formed between the A and B domains in pRB creates a
docking site which binds to the transactivation domain of E2F1-4 45. This interaction
precludes any recruitment of co-activators by E2Fs preventing the upregulation of genes
that are necessary to drive the cell into S-phase (Figure 1.3)58. Finally, by high jacking
E2F DNA binding ability, pRB can act as a scaffold recruiting a variety of chromatin
remodeling factors which can further condense chromatin and prevent the transcription of
E2F targets (Figure 1.3)46,59,60.

1.12

Additional RB binding sites

The characteristic pocket domain of pRB is created through the folding together of
the two cyclin folds in the small pocket of pRB known as the A and B domain (Figure
1.2)45. In addition to contributing to the small pocket binding domain, the B-domain of
pRB also contains a protein interacting region known as the LxCxE binding cleft 47. This
surface is so named as viral oncoprotein binding to pRB is mediated through the LxCxE
peptide sequence present on these viral oncoproteins 61. In addition to being a binding site
for viral oncoproteins that inactivate pRB, several cellular proteins have now been
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Figure 1.3: Regulation of the G1 to S-phase transition by pRB.
In G1 hypophosphorylated pRB binds to E2F/DP heterodimers masking their ability to
stimulate the transcription of genes including but not limited to Mcm3, Rbl1, and, Ccne1,
which are required for cell cycle entry. Additionally, pRB can recruit chromatin
regulatory factors (CRFs) through its LxCxE binding cleft, which compact the DNA at
these genes further repressing transcription. Once the cell is stimulated to divide an
increase in Cyclin/CDK activity, particularly Cyclin E/CDK2 and Cyclin D/CDK4/6,
results in the hyperphosphorylation of pRB. These phosphorylation events lead to large
scale conformational changes to the pRB protein resulting in the disruption of both
E2F/DP interactions and interactions with LxCxE interactors including Chromatin
regulatory factors. E2F/DP heterodimers are then capable of stimulating S-phase required
genes promoting cell cycle entry.
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suggested to interact with pRB through the LxCxE binding cleft47,62. Some of these
proteins include a variety of chromatin remodelers such as HDACs, and Condensin II,
which influence the accessibility of chromatin to transcriptional machinery 44,60,61,63.
Interestingly, as pRB contains no known DNA binding activity, pRB is carried to E2F
target genes essentially changing the E2F-DP transcription factor from a transcriptional
activator into a repressive complex 43. This is accomplished both by the masking of the
transactivation domain on E2F as well as the recruitment of chromatin remodelers which
further compact chromatin preventing transcription specifically at genes regulated by
E2Fs. Finally, a third binding site exists in the C-terminus of pRB which has been less
well characterized as the other two, through which E2F1 can bind to pRB in a unique
conformation51. This interaction has recently been established as a method through which
pRB can inhibit the expression of repeat elements in the genome, such as endogenous
retroviruses60.
The combined action of pRB direct inhibition of the transactivation domain of E2Fs
and the recruitment of chromatin remodelers together comprise a model of cell cycle
restriction and tumor suppression through the which pRB inhibits the expression of genes
required for S-phase progression (Figure 1.3). However recent findings have presented
doubt on this dogma. As an example, the development of mutations which target pRB
transcriptional regulation have relatively minimal effects on the cell cycle regulatory
functions of pRB48,64,65. In this thesis, I explore the importance of the transcriptional
independent functions of pRB and present evidence which disputes this linear view of
pRB function at the G1 to S transition (Figure 1.3).
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1.13 Regulation of pRB activity by CDK
phosphorylation
Expression of pRB is relatively stable throughout the cell cycle and in fact increases
as the cell progresses through S-phase37. This increase is a result of an increase in E2F
activity as the RB1 gene is upregulated by E2F transcription factors66. Given that pRB is
an inhibitor of S-phase entry, increasing expression of RB1 during this transition implies
that the regulation of the RB protein is controlled not through transcription. In addition to
the increased protein levels as the cell progresses through G1 and into S-phase, pRB
becomes hyperphosphorylated (Figure 1.3)67. pRB contains no less than 13 CDK
phosphorylation sites which are located throughout the protein, primarily in intrinsically
disordered regions45. These sites are targeted by Cyclin D/CDK4/6 complexes as well as
Cyclin A/E /CDK2 complexes67. Importantly, Cyclin/CDK complexes are the main
proteins responsible for driving the cell cycle, further supporting the role of pRB as a
repressor of cell cycle progression68.
Once activated, the Cyclin/CDK phosphorylation of pRB results in the compaction of
the pRB protein in such a way that it no longer has open binding surfaces in the large
pocket (Figure 1.4)45. The pRB N-terminus and the pocket domain fold together due to
phosphorylation at T373 (Figure 1.4)45. The linker present in the B-Box becomes
phosphorylated at S608 and S612, and sits in the E2F binding site, and the pRB Cterminus is phosphorylated at residues T821 and T826 causing folding into the LxCxE
binding cleft (Figure 1.4)45. The result of these phosphorylation events is the disruption
of both the pRB-E2F general interaction and the LxCxE binding cleft (Figure 1.4)45.
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Figure 1.4: Compaction of pRB following phosphorylation.
When pRB is hypophosphorylated in the G1 phase of the cell cycle all three of the
interaction surfaces in the pRB large pocket, the E2F general site, LxCxE binding cleft
and the E2F1 specific site are free to bind their ligands. In S-phase, pRB is
hyperphosphorylated leading to compaction of the pRB molecule through the interaction
of the pRB N-terminal domain (RBN) binding to the Pocket domain controlled by
phosphorylation at T373. Furthermore, E2F general interactions and the LxCxE
interactions are disrupted through phosphorylation and docking of the pocket loop (S608,
S612) and pRB C-terminal domain (RBC) (T821, T826) respectively. Yellow circles
denote phosphorylation events.
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Importantly, this compaction of the pRB protein suggests that both the LxCxE binding
cleft and pocket domain are important for cell cycle control. However, classical models
of pRB cell cycle restriction suggest that the LxCxE binding cleft is responsible for
compacting chromatin around E2F target genes preventing their transcription (Figure
1.3)45. If this is in fact the case, disruption of the LxCxE binding cleft would be
unnecessary as loss of E2F interaction with pRB would prevent LxCxE interactors from
associating with E2F target genes. This begs the question, why are LxCxE interactors
also perturbed by pRB phosphorylation? The disruption of the LxCxE binding cleft by
pRB compaction following phosphorylation suggests that the LxCxE binding cleft can
facilitate interactions when not bound to DNA that are important to the tumorsuppressive function of pRB.

1.14

Cell cycle entry as controlled by pRB

Once a cell is stimulated to divide, a variety of signal transduction pathways are
activated leading to cellular division. One critical pathway involved in transducing
extracellular signals to trigger cellular division is the Ras/MAPK pathway2. Following
stimulation by growth factors, membrane spanning cell surface receptor tyrosine kinases
(RTKs) lead to the activation of Ras, triggering a signaling cascade which ultimately
results Myc activation2. Myc then initiates a transcriptional program that promotes cell
cycle progression69. This includes the upregulation of Cyclins, E2Fs, as well as the
repression of CKIs69. The increased CDK4/6 activity through the increased expression of
Cyclin D promoted by Myc activity results in the phosphorylation of pRB at several CDK
sites located in unstructured regions of the protein 70,71. These phosphorylation events
trigger the conformational shift in pRB described above resulting in the disruption of
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pRB function45. This structural change prevents both the pocket of pRB from associating
with E2Fs as well as the large variety of LxCxE interactors from binding the LxCxE
binding cleft45. Activator E2Fs are then free to recruit transcriptional co-factors
enhancing the transcription of S-phase genes including Cyclins, replication complex
members, and many other genes required for cellular division 54. Critically, one such E2F
target gene is CCNE1 which encodes for Cyclin E which together with CDK2 forces the
G1 to S-phase transition committing the cell to the cell cycle (Figure 1.5)67,72. This feed
forward loop ensures that the cell proceeds through the entire cell cycle regardless of
continual stimulation73. This allows pRB to translate the various growth stimulating
signals into an all or nothing E2F response, which, once activated, will complete the cell
cycle independent of stimulation by serum or other growth factors 73. Taken together this
suggests that pRB is a critical gate-keeper of the G1 to S-phase transition, and ultimately
the cell division cycle.
The study of pRB-E2F interactions has largely focused on the transition from the G1
to S-phase of the cell cycle. As such the majority of experiments have been performed in
quiescent cells that are stimulated to divide43. Coincident with cell cycle entry, pRB
becomes hyperphosphorylated and E2F target gene expression levels increase 74,75.
Importantly, activator E2Fs (E2F1-3) have been shown to be required to allow for cell
cycle entry56,74,75. Finally, the overexpression of E2F1 in quiescent cells was sufficient to
drive the cell into S-phase as denoted by BrdU incorporation76. While this model has
been well established for cell cycle entry far fewer studies have looked at cell cycle exit,
an oversight pointed out in 1998 by Dyson in his seminal review 43.
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Figure 1.5: Schematic representation of the pRB pathway.
The activity of pRB is controlled largely by phosphorylation. When there is increased
Cyclin D/CDK4 activity due to increased expression or loss of p16 inhibition, pRB
becomes hyperphosphorylation. This allows for the release of E2F transcription factors
and the upregulation of S-phase genes including Cyclin E. Cyclin E/CDK2 complexes are
responsible for further inactivating pRB through hyperphosphorylation as well as driving
the cell into S-phase.
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1.15

Consequences of pRB loss in vivo

In 1992, to better understand the role of the Rb1 gene, three knockout mouse models
of pRb loss were created resulting in animals which do not express pRb 77-79. Loss of pRb
is relatively well tolerated in early embryogenesis and Rb1-/- knockout embryos are
indistinguishable from littermates77. However, loss of pRb results in embryonic lethality
between E14 and E15 days of gestation77. This is largely attributed to hyperplasia
occurring in the trophoblasts of the placenta80. This overgrowth leads to decreased space
between the mother and fetal blood supply and subsequent reduction of nutrient flow to
the developing embryo80. Interestingly if the Rb1-/- embryo is supplemented with a
normal placenta the embryos can develop normally until birth 80,81. These animals die
shortly after birth due to inadequate skeletal muscle development in the diaphragm
preventing the newborn lungs from inflating properly81. Additionally, fibroblasts isolated
from Rb1-/- embryos have demonstrated that pRB plays key roles in the ability of cells to
respond appropriately to a variety of cellular stressors including DNA damage, serum
starvation, TGF-β treatment, expression of p16 as well as others 64,82-84. Consistent with
the established paradigm of pRB-mediated regulation of cell cycle control through the
disruption of E2F driven transcription, codeletion of E2f1 or E2f3 with Rb1 loss, partially
rescued pRb deletion resulting in prolonged viability of embryos extending life from E14
to E17.5 days54,85,86.
While complete Rb1 knockout is embryonic lethal, mice which are heterozygous
for the Rb1 gene (Rb1+/-) do develop normally into adulthood77,87,88. Beginning around
300 days of age Rb1+/- mice develop pituitary adenocarcinomas arising from the
intermediate lobe of the pituitary64,87-89. Importantly, this occurs following loss of

22

heterozygosity of the wild-type allele of Rb190. This genetic alteration results in an Rb1
null cell which has already bypassed all the developmental problems associated with Rb1
homozygous deletion77. These cells then have perturbed cell cycle control, and following
additional mutations in critical pathways can develop into pituitary tumors 64,87,88.
Furthermore, several groups have created conditional knockout models of pRB91-94.
While it is beyond the scope of this thesis to discuss all the various conditional knockouts
of pRb, some studies have demonstrated a loss of cell cycle control and hyperplasia in
conjugation with deregulation of E2F transcription factor activity however, this is far
from consistent and E2F target gene expression changes are not always the most dramatic
shifts in the transcriptome91-94.
Lastly, 2 groups in 1994 independently developed chimeric mouse models of pRb
loss95,96. These animals contained cells harboring homozygous deletion of the Rb1 gene
as well as heterozygous Rb1+/- cells95,96. Surprisingly, the contribution of some
heterozygous Rb1+/- cells is sufficient to allow for proper development, despite the a
large proportion of Rb1-/- cells in these mice making up 40% to 80% of a given tissue 96.
Similar to Rb1+/- mice these chimeric animals develop pituitary adenocarcinomas at an
accelerated rate96. These studies demonstrate that even in the case of a complete loss of
pRb, cells they can still differentiate and contribute to tissues in an adult animal.
Overall, mouse models lacking pRb have played a significant role in determining the
effect of pRB on development as well as tumorigenesis. Homozygous deletion of Rb1 is
embryonic lethal in mice due to hyperplasia of the placenta and subsequent starvation of
the embryo77,80. Interestingly, Rb1+/- animals bypasses the embryonic lethality, however
eventually loss of the wild-type allele of Rb1 allows for the development of a tumor
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phenotype later in life (~300 days)64,87-89. This type of genetic background is more
representative of children with retinoblastoma. Most often, these children inherent one
copy of the RB1 gene which is mutated and develop the second mutation somatically25.
This eventually leads to the formation of the retinoblastoma. This finding that both alleles
of the Rb1 gene must be deleted to form tumors in mice supports Knudsen’s two hit
hypothesis25,90.

1.16

Regulation of pRB through CDK phosphorylation

pRB is typically regulated through phosphorylation67. This phosphorylation leads to
the compaction of the pRB protein blocking the various binding surfaces in the large
pocket, releasing E2Fs, and allowing the cell to move into S-phase (Figure 1.4)45. These
phosphorylation marks are added by a family of proteins known as the Cyclin dependent
kinases (CDKs)68. These complexes are made up of two individual proteins, the catalytic
CDK protein and a regulatory Cyclin component68. In general, CDK levels are relatively
stable throughout the cell cycle however the specific Cyclins associated with them
fluctuate greatly depending on the phase of the cell cycle (Figure 1.6)4. This ensures that
the correct CDK is activated during the right phase of the cell cycle, resulting in one
complete round of DNA synthesis and division only when instructed to do so by various
signals.

1.17

CDK activity throughout the cell cycle

There are 4 main Cyclin/CDK pairs that regulate the mammalian cell cycle 68.
Beginning in G1, a variety of growth factors such as EGF bind to receptors on the surface
of cells2. This signal is then propagated through a number of signalling kinases, in the

24

Figure 1.6: Expression patterns of various Cyclins control cell cycle progression.
Idealized expression patterns of 4 key Cyclins over the course of the cell cycle. Once
expressed each Cyclin can associate with its catalytic partner CDKs facilitating the
phosphorylation of substrates necessary for that particular section of the cell cycle. In
general, Cyclin D is expressed beginning in G1 and persists through mitosis. By
comparison Cyclin E, Cyclin A, and Cyclin B all peak at more defined times, G1-S, G2,
and mitosis respectively.
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case of EGF, the Ras, Raf, MAPK pathway97. The expression of Cyclin D is then
upregulated, which can bind to its catalytic subunits, CDK4 or CDK6 97. This complex is
then able to bind to and phosphorylate pRB98. E2F-DP transcription factors are then free
to activate transcription of S-phase required genes98. One critical gene activated by E2F
transcription factors is CCNE1 which encodes for the Cyclin E protein72. Once in
complex with CDK2, Cyclin E/CDK2 phosphorylates a variety of targets that are
necessary for DNA synthesis including the firing of pre-replication complexes68,99.
Importantly, Cyclin E/CDK2 complexes also phosphorylate pRB ensuring that the cell
continues through S-phase and completes cellular division before returning to a G1
state100. As the cell progresses through DNA synthesis phase, Cyclin A, another E2F
target gene, replaces Cyclin E as the regulator subunit of CDK2 68,101. Finally, after the
cell has completed DNA synthesis and traversed the G2 phase, the final of the 4 main
Cyclin/CDK complexes Cyclin B and its binding partner CDK1 drive the cell through
mitosis68. These 4 complexes together control the cell cycle68. Importantly, cell cycle
regulation by Cyclin A/CDK2 and Cyclin B/CDK1 complexes can only be temporarily
stalled via the DNA damage and spindle assembly checkpoints 19,21. This leaves regulation
at the G1 to S-phase boundary the critical road block in the prevention of aberrant cell
growth24. As such this transition is highly regulated through both Cyclin/CDK activity as
well as by pRB, and pathways influencing these genes are often targets of cancer causing
mutations30,102. These two pathways form a critical hub through which a variety of signals
are funneled determining if the cell will divide or not.
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1.18 Cyclin dependent kinase inhibitors and their role in
regulating the cell cycle.
Transcriptional control of Cyclins ensures that the appropriate CDK is activated
during the proper phase of the cycle103. In addition to this regulation, Cyclin/CDK
complexes are further controlled by 2 families of CKIs which further influence the cell
cycle104,105. The two families are divided up based on the CDK complexes which they can
inhibit104,106. First, the INK4 family consists of 4 members p14, p15, p16, and p18, all of
which are specific inhibitors of Cyclin D/CDK4/6 complexes and are involved in cellular
senescence, apoptosis and DNA repair (Figure 1.7)105,106. As these proteins specifically
influence Cyclin D/CDK4/6 activity, their role is primarily contained to the G1 phase of
the cell cycle105,106. The second family of CKIs is the CIP/KIP family which is made up
of p21, p27 and p57 (Figure 1.7)104. These proteins more broadly influence the activity
of CDKs as there can inhibit all 4 major Cyclin/CDK complexes which drive the
mammalian cell cycle68,104. Similarly, CIP/KIP family proteins are responsible for
arresting the cell in response to a variety stimuli such as genetic insults or loss of mitogen
signalling107. This family is more universal than the INK4 family as they can inhibit
many CDKs and as such can elicit a cell cycle arrest in multiple phases of the cell
cycle108.
While the three members of the CIP/KIP family of proteins are capable of interacting
with the same Cyclin/CDK complexes, each member is expressed in different
circumstances104. In particular, p21 is critical to the DNA damage response and its
expression is directly regulated in response to p53 activation 109. By contrast, p27 is more
typically associated with the G1 phase of the cell cycle and is involved in cell cycle arrest
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Figure 1.7: Schematic representation of the G1-S-phase transition of the cell cycle.
Following mitogenic stimulation in the G1 phase of the cell cycle an increase in Cyclin
D/ CDK4/6 activity hyperphosphorylates pRB, releasing the E2F/DP transcription factor.
Once free, E2F upregulates several genes including CCNE1, encoding for Cyclin E,
which together with CDK2 can also phosphorylate pRB. This creates a feed forward loop
ensuring that once started the cell cycle is completed. In addition, two families of Cyclin
dependent kinase inhibitor CKIs restrict the activity of Cyclin/CDKs. The Ink4 family
consists of p14, p15, p16, and p18, and inhibits Cyclin D/ CDK4/6 complexes. The
CIP/KIP family consists of p21, p27, and p57 which can broadly inhibit Cyclin/ CDK
complexes. The activity of these CKIs are influences by both extracellular cues such at
mitogen deprivation as well as intracellular cues such as DNA damage. The overall
balance of Cyclin/CDKs and CKIs determine whether the cell will enter the cell cycle.
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following growth factor deprivation, TGF-β treatment, as well as contact inhibition 104.
Finally, p57 appears to be involved primarily in development as p57 knockout animals
die immediately following birth due to several developmental defects including cleft
plate, abdominal muscle defect as well as skeletal defects 104. The balance of
Cyclin/CDKs and CKI expression together determine the overall activity of the various
Cyclin/CDK complexes and ultimately whether the cell will undergo division 104,105,108.
Additionally, this interplay also underpins the cellular arrest in response to various
stimuli such as DNA damage, quiescence induction and differentiation 104.
The precise balance of Cyclin/CDK complexes to CKIs is critical to determine
whether a cell will traverse the G1 to S phase checkpoint. Once kinase activity, in
particular Cyclin E/CDK2, reaches a certain threshold the cell activates a feed forward
cascade which commits the cell to division110. This feed forward loop is initiated by
Cyclin E/CDK2-mediated phosphorylation of pRB110. As discussed above these
phosphorylation events result in a conformational change in the pRB molecule, releasing
E2Fs causing the expression of CCNE1 and CCNA2, both of which complex with CDK2
further phosphorylating pRB molecules45,72,101. This loop ensures that pRB is maintained
in a hyperphosphorylated state throughout S-phase and G2 allowing for the expression of
E2F target genes which are needed to complete DNA replication and the cell cycle 67. In
addition to phosphorylating pRB, Cyclin/CDKs also target a variety of cellular proteins,
including transcription factors and most importantly activate a cascade leading to the
firing of replication origins, beginning the process of DNA replication 68,111. Importantly,
while pRB can influence cell cycle progression at the G1 to S-phase boundary, ultimately
S-phase entry is determined by the overall level of CDK activity and in particular Cyclin
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E/CDK2 activity (Figure 1.7)68,111. Therefore, the combined inputs of pRB-mediated
repression of CCNE1 and the expression of CKIs control CDK activity and cell cycle
progression. Both the pRB and CKI pathways play integral roles in regulating CDKs and
the cell cycle and the interconnectedness of these two pathways, suggests that there could
be some level of redundancy involved between them (Figure 1.7).

1.19

Disruption of the pRB pathway in cancer

Given that pRB acts as a critical gate-keeper to cellular division it is perhaps
unsurprising that the pRB pathway is perturbed in a large majority of human cancers 30.
Interestingly however, mutations in pRB itself is relatively rare outside of small cell lung
cancer, retinoblastoma and osteosarcoma30. Instead upstream disruption of the kinases
involved in phosphorylating pRB are targeted for mutation resulting in constitutive pRB
hyperphosphorylation, inhibiting its various functions30. The complete disruption of the
pRB protein by phosphorylation in the majority of cancers suggests pRB performs
multiple critical functions to maintain cell cycle control and is not limited solely to the
repression of E2Fs30.
Early Saos-2 cell cycle arrest assays demonstrated that the minimal region of pRB
capable of arresting the cell cycle was also capable of binding E2Fs 49,50. Importantly, this
fragment also contains the LxCxE binding cleft which binds several cellular proteins
(Figure 1.2B)47,49,50. More recently, Soas-2 arrest assays were performed using the partial
penetrant familial retinoblastoma mutant RB1R661W 112. This mutant has defective binding
to E2F-DP heterodimers and gives rise to benign retinomas and rare retinoblastoma in
children112,113. Surprisingly however, this mutant version of pRB is still capable of
restricting the cell cycle when expressed in Saos-2 cells despite the apparent lack of E2F
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repression112. It is important to note, however, that the RB1R661W mutant does have partial
disruption of LxCxE interactions and the G1 cell cycle arrest conveyed in Saos-2 cells is
unstable112. These results provided an important basis for the study of pRB-mediated cell
cycle control independent of E2F, however given the caveats associated with the
RB1R661W mutation a new model was needed.

1.20

Development of the Rb1G/G mouse model

Building on the results from Sellers et al. demonstrating that the E2F-binding
deficient mutant RB1R661W could induce a G1 cell cycle arrest in Saos-2 cells, Cecchini et
al. developed a targeted mutation in the pRB pocket which successfully disrupted the
ability of pRB from associating with E2Fs through the pocket domain (See appendix
A)64,65. This mutation referred to as the RB1G mutation contains two amino acid
substitutions (K467E and R548E) which change key pocket residues from a basic charge
to an acidic one64. This therefore prevents the pocket from binding to the acidic regions in
the transactivation domain of E2F leading to charge repulsion and an inability to bind
pRB65. As expected, cells homozygous for the Rb1G mutation do show a loss of pRb
binding to E2F target gene promoters as pRb can no longer be carried to promoters via
E2Fs64. Consistent with this finding, the depletion of pRb from the DNA results in an
increase in the expression of E2F target genes64. Surprisingly, despite the loss of E2F
repression caused by the Rb1G mutation, these cells eventually give rise to viable animals,
which display no overt phenotype64. These mice developed normally, are fertile and show
no tumor phenotype or lifespan changes64. This is in direct contrast to complete knockout
of the Rb1 gene, which, as previously mentioned is embryonic lethal between E14 and
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E1577. Taken together, this suggests that E2F regulation by pRB is dispensable for pRBmediated development and tumor-suppression.
The role for pRB in cell cycle control has been well established as cells lacking pRB
are not capable of appropriately restricting cell cycle entry following treatment with a
variety of conditions82-84. Interestingly, when Rb1G/G cells were deprived of serum or
treated with ionizing radiation, a successful G1 cell cycle arrest occurred as efficiently as
wildtype cells64. Furthermore, even in this context, Rb1G/G cells still maintain elevated
levels of E2F target gene expression, equivalent to Rb1-/- cells which failed to arrest64.
These experiments indicated that E2F regulation by pRB is dispensable to enact a G1 cell
cycle arrest in response to cellular stressors. While this finding was surprising, it is
important to note that the majority of studies highlighting the importance E2F in cell
cycle focus on its ability to stimulate the entry into S-phase of the cell cycle 43. However,
consistent with the importance of E2F target gene induction in cell cycle entry, Rb1G/G
cells stimulated to divide from a quiescent state entered the cell cycle far earlier than
wildtype cells and at a similar rate to Rb1-/- cells64.
This study identified that the linear model of pRB regulation of the cell cycle through
the repression of E2Fs is incomplete, at least for cell cycle exit 64. Therefore, additional
pathways must be active to arrest the cell following treatment with these agents. As
discussed above, Cyclin/CDK complexes are crucial to cell cycle progression 68. When a
cell must arrest the cell cycle due to DNA damage or serum deprivation CKIs become
active, inhibiting the activity of Cyclin/CDK complexes104,105. This then leads to the
hypophoshorylation of pRB preventing the activity of E2F transcription factors.
Additionally, the inhibition of Cyclin E/CDK2 by CKIs prevent the firing of replication
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origins which is the definitive transition from G1-S phase111. Furthermore, as Cyclin E
expression is regulated by E2F activity, Cyclin E/CDK2 therefore is upstream and
downstream of pRB regulation72. Therefore, in the context of Rb1G/G cells, perhaps the
arrest is achieved through the direct inhibition of Cyclin E/CDK2, independent of E2F
repression. Lastly, this function must be pRB dependent as Rb1-/- cells are incapable of
initiating an arrest under the same conditions that lead to an arrest in Rb1G/G cells64.

1.21 E2F independent regulation of the cell cycle by
pRB
One possible explanation for the G1 cell cycle arrest in Rb1G/G cells which is
independent of E2F regulation is through the CKI p2764. Previous work has identified
that RB1R661W can initiate a G1 cell cycle arrest in Soas-2 cells despite lacking the ability
to associate with E2Fs112. Ji et al. confirmed this finding and showed that both wild-type
RB1 and the mutant RB1R661W increased the protein level of p27 coincident with cell cycle
arrest in Saos-2 cells114. Higher expression of p27 in turn can inhibit the activity of
Cyclin E/CDK2 and prevent cell cycle progression68. Importantly, p27 has also been
implicated in regulating a variety of oncogenic and tumor-suppressive functions in
addition to CDK inhibition115. These non-canonical functions of p27 will be discussed in
greater detail at the end of this thesis as they will be more relevant in the context of some
experiments performed. Finally, given the inability of RB1R661W to associate with E2Fs,
any regulation must exist independent of transcriptional control 113.

1.22

Modulation of p27 activity through the cell cycle.

The level of p27 is generally controlled by the rate at which it is degraded (Figure
1.8)99. During cell cycle initiation, p27 is degraded through the combined activity of
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Figure 1.8: Schematic representation of E2F-independent pRB-mediated cell cycle
regulation through the pRB-SKP2-p27 axis.
pRB associates with both the anaphase promoting complex containing Cdh1 (APC Cdh1)
and SKP2. By serving as a scaffold, pRB facilitates poly-ubiquitination (Ub) of SKP2 by
the APCCdh1. The degradation of SKP2 prevents p27 polyubiquitination by the SCF
complex as SKP2 is required for p27 targeting. The pRB-mediated ubiquitination and
subsequent degradation of SKP2 by the APCCdh1 and the proteasome results in the
stabilization of p27 and inhibition of the cell cycle.
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CDK phosphorylation and degradation by the proteasome allowing for the cell to
progress into S-phase99. This degradation is primarily controlled by the SCF complex
containing the targeting E3 ligase SKP2116. Following CDK phosphorylation of p27,
SKP2 can associate with p27 resulting in the poly-ubiquitination of p27 targeting it to the
proteasome for degradation116. As SKP2 is the protein involved in targeting p27 for polyubiquitination, this reaction is controlled by the level of available SKP2 to associate with
the SCF complex116.
The involvement of pRB in regulating p27 in this manner has been analyzed in
two landmark studies114,117. Collectively, these reports demonstrate that pRB is capable of
binding to both SKP2 as well as the Cdh1 containing APC complex (APC Cdh1) (Figure
1.8)114,117. Importantly, APCCdh1 has ubiquitin ligase activity and is active in G1 to polyubiquitinate a large variety of proteins, including those involved in mitosis leading to
their degradation118. This ensures that the cell is returned to a G1 state prior to re-entering
the cell cycle118. One such target of the APCCdh1 is SKP2, which when degraded,
effectively stabilizes p27 (Figure 1.8)116,119. The finding that pRB can bind to both
APCCdh1 and SKP2 suggest that pRB may be acting as a scaffold to facilitate the
degradation of SKP2114,117. Furthermore, the ability of pRB to interact with SKP2 and
stabilize p27 is maintained when the RB1R661W is expressed in Soas-2 cells indicating that
E2F binding is not required for this process 114.
This second axis of pRB-mediated cell cycle control is particularly intriguing as it
appears to be E2F independent and functional in cells containing RB1R661W114. Previous
work has created a mouse model harboring the equivalent mutation to R661W in mice
(Rb1R654W) which displayed a similar phenotype to Rb1-/- animals dying embryonically
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due to placental defects120. This effect is less severe however as Rb1R654W animals survive
slightly longer dying around E15 to E17120. Importantly, in addition to disrupting pRBE2F interactions, this mutation also partially disrupts LxCxE interactors which may also
have roles in regulating the cell cycle121. By contrast, the Rb1G/G mutant mice developed
by Cecchini et al. contain a much more targeted mutation which specifically eliminated
pRB-E2F interactions through the general site while maintaining LxCxE interaction and
the pRB-E2F1 specific interaction64. Moreover, Rb1G/G mutant animals are viable and
show no long-term consequences of E2F deregulation64. This implies that pRB must be
playing additional roles to regulate the cell cycle independent of E2F repression. The
pRB-SKP2-p27 axis of regulation discussed above is an intriguing possibility to account
for the dispensability of pRB-E2F interactions (Figure 1.8). The Rb1G/G model allows for
the unique opportunity to study E2F independent regulation of cell cycle control and
tumor suppression by pRB, including the pRB-SKP2-p27 axis, in an in vivo context.

1.23

Objectives

One of the main functions of pRB-mediated cell cycle control is the repression of E2F
transcription factors preventing the upregulation of genes required for S-phase
progression10. However, considering recent evidence discussed in the introductory
chapter it is now clear that explanation is not complete 64,112,114. Instead, it suggests that
pRB can regulate the cell cycle though multiple pathways influencing the G1 to S-phase
transition. The Rb1G/G mouse model developed in our lab provides an excellent tool to
study these alternative functions of pRB64. Given the normal development and lifespan of
the Rb1G/G mice we can combine these mice with other mutant mouse strains to attempt
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to recapitulate the phenotype of Rb1-/- mice thereby accounting for all the functions of
RB-mediated cell cycle control and tumor suppression64,77.
In the first chapter I characterized the pRB-p27 axis of pRB-mediated cell cycle
control. I hypothesized that the maintenance of cell cycle control in Rb1G/G cells is due to
the stabilization of p27 mediated by the LxCxE binding cleft on pRB 114,117. By combining
our Rb1G/G mutant mice with those harboring a null allele for p27 (Cdkn1b-/-), we could
address the importance of the pRB-p27 axis of pRB tumor suppression both in cell
culture and in vivo122. Using double mutant Rb1G/G; Cdkn1b-/- cells as well as single
mutant controls I analyzed the ability of cells to arrest the cell cycle under different
treatment conditions. Furthermore, we were then able to confirm these results in the
double mutant Rb1G/G; Cdkn1b-/- mice. These results will be discussed in detail in chapter
2 of this thesis.
In addition to the pRB-mediated regulation of E2F and p27, several other proteins
interact with pRB and as such may influence the cell cycle or tumor-suppressive
properties of pRB47,51,62. As such we hypothesized that the three distinct binding surfaces
in the pRB large pocket discussed above play a role in regulating the function of pRB.
Using mutations developed in our lab we could individually and simultaneously disrupt
the general pRB-E2F pocket, the LxCxE binding cleft, and the pRB-E2F1 specific
interaction62,65,123. Following expression of these mutant versions of RB1 in Saos-2 cells
we can directly measure the contribution that each individual binding surface makes
towards pRB-mediated G1 arrest. Further, by intercrossing our Rb1G/G; Cdkn1b-/- mice
generated in chapter two into the E2f1 null background we could create an in vivo model
of disruption of all three binding surfaces. Analysis of livers was carried out to determine
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if we had in fact recapitulated Rb1 loss in adult tissues. A detailed description of the
results of these experiments can be found in chapter 3 of this thesis.
pRB pathway mutations have been well documented in a variety of human cancers 30.
As discussed in the introduction, the majority of these mutations occur upstream of pRB
leading to hyperphosphorylation and inactivation of the pRB protein 30. This finding
suggests that single point mutations which target a specific domain such as the E2F
binding pocket on pRB would be ineffective in eliminating pRB functionality. This
hypothesis is further collaborated by the lack of effect on tumor suppression displayed by
the Rb1G mutation64. However, the disruption of pRB-E2F interactions would reduce the
pathways through which pRB can regulate the cell cycle and thus we hypothesized that
Rb1G/G would display increased sensitivity to tumorigenesis when combined with
activated oncogenes or loss of tumor-suppressors. In chapter 4 I tested this hypothesis by
combining our Rb1G/G mutant animals with three different genetic backgrounds. The
Rb1G/G mutation was introduced into mouse lines containing oncogenic KrasG12D, or
deletions of p53 or p21 tumor suppressors64,124-127. Detailed explanations of the results of
these experiments are presented in chapter 4.
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Chapter 2

2

Interchangeable roles for E2F transcriptional repression
by the retinoblastoma protein and p27KIP1-CDK
regulation in cell cycle control and tumor suppression.
2.1

Abstract

The mammalian G1-S phase transition is controlled by the opposing forces of Cyclin
dependent kinases (CDK) and the retinoblastoma protein (pRB). Here we present
evidence for systems level control of cell cycle arrest by pRB-E2F and p27-CDK
regulation. By introducing a point mutant allele of pRB that is defective for E2F
repression (Rb1G) into a p27KIP1 null background (Cdkn1b-/-), both E2F transcriptional
repression and CDK regulation are compromised. These double mutant Rb1G/G; Cdkn1b/-

mice are viable and phenocopy Rb1+/- mice in developing pituitary adenocarcinomas,

even though neither single mutant strain is cancer prone. Combined loss of pRB-E2F
transcriptional regulation and p27 KIP1 leads to defective proliferative control in response
to various types of DNA damage. In addition, Rb1G/G; Cdkn1b-/- fibroblasts immortalize
faster in culture and more frequently than either single mutant genotype. Importantly, the
synthetic DNA damage arrest defect caused by Rb1G/G; Cdkn1b-/- mutations is evident in
the developing intermediate pituitary lobe where tumors ultimately arise. Our work
identifies a unique relationship between pRB-E2F and p27-CDK control and offers in
vivo evidence that pRB is capable of cell cycle control through E2F independent effects.

2.2

Introduction

Regulation of the cell cycle is critical to maintain cellular homeostasis and to
prevent the development of cancer 1. Mammalian cell division is primarily controlled at
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the G1-S phase transition, and the moment of commitment is often described as the
restriction point 2. Commitment to enter the cell cycle is controlled by two opposing
forces; the retinoblastoma protein family (including pRB) that blocks entry, and Cyclin
Dependent Kinases (CDKs) that drive advancement into S-phase 3. The RB protein
antagonizes S-phase entry by repressing E2F regulated genes necessary for DNA
replication 4. Working in opposition to pRB are CDKs 5, in particular Cyclin D and E
associated kinases phosphorylate and inactivate upstream regulators of cell cycle entry
including pRB and p27KIP1, as well as stimulate the activation of downstream effectors of
DNA replication 6,7. While this suggests CDKs control pRB, a key target gene that is
repressed by pRB-E2F is CCNE1 that encodes Cyclin E, this creates a regulatory loop
whereby Cyclin E/CDK2 becomes maximally active at almost the same time pRB is
maximally phosphorylated and finally releases all E2Fs 4. In addition, CDK2’s principal
negative regulator p27KIP1 is phosphorylated and targeted for degradation at virtually the
same time 8. Due to this interplay between pRB and CDK activity, it has been difficult to
place one upstream of the other in a regulatory pathway 4. Numerous studies suggest that
either pRB-E2F or p27KIP1-CDK2 interactions are essential for controlling quiescence or
cell cycle entry commitment 9-17. For this reason, control of the G1-S phase transition
remains unclear. Furthermore, since much of the literature investigating G1-S regulation
focuses on regulatory events during cell cycle entry 4,18, this leaves the roles for pRB-E2F
and p27KIP1-CDK interactions in cell cycle exit much less explored.
Cell cycle arrest by pRB has long been attributed to E2F regulation because the
minimal deletion mutant of pRB that is capable of binding E2Fs can block proliferation
of Saos-2 cells 19,20. These studies revealed a close correlation between pRB-E2F
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binding, transcriptional repression, and cell cycle arrest 20,21. However, E2F binding
mutants of pRB have a surprising retention of growth control activity in this assay 22-24,
suggesting that other mechanisms may contribute. Given that cell cycle control
ultimately impinges on CDK regulation, a number of studies have connected pRB growth
arrest activity in Saos-2 cells to CDK regulation through p27 KIP1 25-27. First, E2F binding
deficient mutants of pRB induce p27 KIP1 expression in Saos-2 cell cycle arrest assays, and
p27 expression is required for these mutants of pRB to induce arrest 27. Secondly, pRB
stabilizes p27KIP1 expression during induction of a G1 arrest quite rapidly, and this
precedes the decline in E2F regulated targets by at least 24 hours, suggesting CDK
regulation occurs first 26. Moreover, Ji et al., also demonstrated that pRB is capable of
binding and inhibiting the function of Skp2, the E3 ligase targeting subunit responsible
for poly-ubiquitination of p27 26. Consistent with this, the increases in p27 levels seen
following pRB expression in Saos-2 cells correlate with a decrease in Skp2 levels 25.
Binne et al., showed that APC complexes containing Cdh1 are capable of using pRB as
an adaptor for Skp2 binding and ubiquitination, thereby stimulating Skp2 degradation and
promoting the stabilization of p27 25. Collectively, these studies connect pRB regulation
of the cell cycle to p27. However, the shortcoming of this work is its dependence on
ectopic pRB expression, a physiological context where pRB regulation of p27 genuinely
contributes to proliferative control decisions has yet to emerge. A number of genetic
crosses indicate that Skp2 loss can suppress pituitary tumorigenesis in Rb1+/- mice 28,
even in combination with p53 deficiency 29. However, efforts to find p27 dependent
growth arrest in tissues of these mice have been confounded by other cellular effects such
as apoptosis in the intermediate lobe of the pituitary 28. This has prevented the
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observation of proliferative control decisions in these cells that use a pRB-p27 axis. For
this reason, the pRB-p27 connection in proliferative control remains compelling, but its
lack of detection in an endogenous scenario is a critical gap in our knowledge.
To study E2F independent functions of pRB at an endogenous level, we
developed a mutant mouse model in which pRB binding to E2Fs is disrupted by R461E
and K542E mutations (called Rb1G) 30. Importantly the Rb1G mutant protein is expressed
at wild type levels and makes normal interactions with LXCXE motif containing proteins
30

. Surprisingly, we found that this mutation had little effect on control of cell

proliferation, as Rb1G/G fibroblasts are capable of responding to serum starvation, p16
expression, DNA damage, and myogenic differentiation and in all cases show wild type
responses 30. In this study, we find that p27 expression levels are higher in Rb1G/G
fibroblasts. In addition, double mutant Rb1G/G and p27 deficient cells are defective for
growth arrest in response to DNA damage in a manner that resembles Rb1-/- cells,
including misregulation of CDK2 activity. Furthermore, while developmentally
unremarkable, Rb1G/G; Cdkn1b-/- mice display a highly penetrant tumor phenotype.
Together our study demonstrates systems level redundancy between pRB-E2F regulation
and p27-CDK2 control, as the combined loss displays cell cycle defects that are absent
from either single mouse mutant. In addition, this work provides proof of principle for
transcription independent coordination between the RB and the CDK pathways in
endogenous growth control.
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2.3
2.3.1

Materials and Methods
Cell culture methods.

Mouse embryonic fibroblasts (MEFs) were derived from E13.5 embryos of the
indicated genotypes. Asynchronous cells were cultured using standard methods in
Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum (FBS), 2mM Lglutamine, 50U/ml penicillin and 50µg/ml streptomycin. Cells subjected to serum
deprivation were cultured in the above media however only containing 0.1% FBS.

2.3.2

DNA damage induction.
MEFs subjected to gamma irradiation were plated at low density at passage 4. The

next day media was changed prior to exposure to a cobalt 60 source until a dose of 15Gy
was received. Media was changed again the next morning and cells were harvested 48
hours after treatment. Cells treated with DNA damaging agents cisplatin and H 2O2 were
plated at low density at passage 4 then the next day switched to media containing the
indicated drug at a concentration of 1µM for cisplatin and 250µM for H 2O2. Cells were
incubated in the drug containing media for 48 hours before harvest for downstream
applications.

2.3.3

Cell cycle analysis.
Cells were pulsed with BrdU under different growth conditions: asynchronous

culture, serum deprived, serum stimulated, or various sources of DNA damage for a
duration of 2 hours. Cell cycle analysis was then carried out following previously
published protocols 31.
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2.3.4

mRNA quantitation.
RNA isolation was carried out using Trizol reagent according to manufacturers

instructions and previously published protocols 30. mRNA levels of p27 were analyzed by
qRT-PCR using iQ Sybr-green Super Mix (Bio-Rad) and the following primers against
p27 and GAPDH: p27 Fwd (5`AGATACGAGTGGCAGGAGGT 3`), p27 Rev (5`
ATGCCGGTCCTCAGAGTTTG 3`), GAPDH Fwd (5`
GCACAGTCAAGGCCGAGAAT 3`), GAPDH Fwd. (5`
GCCTTCTCCATGGTGGTGAA 3`). Expression levels of common E2F target genes:
Pcna1, Ccne1, Ccna2, Tyms, Rbl1, and Mcm3 were determined using the Quantigene
Plex 2.0 reagent system from Affymetrix as previously described 32. Expression levels
were normalized to Actin.

2.3.5

3T3 Assay.
Passage 3 MEFs were plated at a density of 1x106 cells per 10cm culture dish in

Dulbecco’s modified Eagle’s medium containing 10% Calf serum, 2mM L-glutamine,
50U/ml penicillin and 50µg/ml streptomycin. Three days after plating cells were counted
and replated at the same density, 1x106 cells per 10cm dish. This procedure was repeated
until passage 20. Population increase was calculated according to the following formula:
(Log10(recovered/seeded)/Log102. Cells were considered successfully immortalized if the
population growth was positive at the end of the 20 passages.

2.3.6

Protein interaction analysis and western blotting.
Nuclear extracts were prepared from MEFs and western blotting was carried out

using previously described protocols 30. Antibodies raised against p27 (C-19: sc-528) and
Histone H3 (ab70550) were used for western blotting. pRB containing complexes were
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immunoprecipitated from whole cell extracts using anti-E2F3 C-18 (Santa Cruz) bound
to G-sepharose beads (GE-healthcare). IPs were rocked for 1h at 4°C then washed twice
with IP wash buffer (10mM Tris pH 7.5, 200mM NaCl, 1.5mM MgCl 2, 2mM EDTA,
0.1% NP-40) and boiled in SDS-PAGE sample buffer. Samples were western blotted
using standard techniques. E2F3 was detected by PG37 (Upstate), pRB was detected by
G3-245 (BD Pharmingen), and Actin was detected with monoclonal antibody AC-74
(Sigma).

2.3.7

Phenotypic analysis of animals.
Cdkn1b-/- mice (B6.129S4-Cdkn1btm1Mlf/J) have been described previously and

were obtained from Jackson Laboratory and genotyped as recommended 33. Rb1G/G mice
were genotyped as previously described 30. All animals were housed and handled as
approved by the Canadian Council on Animal Care. Mice were monitored for tumor
development. Mice were sacrificed at natural endpoint. Survival data were subjected to
Kaplan-Meier analysis, and significant differences were compared using a log rank test.
For DNA damage experiments, pregnant mothers at day 13.5 of gestation were subjected
to 10Gy IR followed by a 2h pulse of BrdU 4 hours after IR treatment.

2.3.8

Histology and microscopy.
E13.5 embryos treated with 10Gy of IR were removed from the uterus and fixed

whole in PBS containing 4% PFA for 24h. Next, they were placed in PBS containing
30% sucrose to dehydrate the samples for a minimum of 3 days. Embryos were then dried
and mounted in Cryomatrix (Thermo Scientific 6769006), frozen using liquid nitrogen
and stored at -80°C 34. Sagittal pituitary sections were cut using a Leica cryostat (CM
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3050S) in 8µm sections and mounted on slides which were stored at -80°C. Slides were
acclimated to room temperature prior to staining.
For BrdU staining, slides were rehydrated in PBS and inserted into a Shandon
Sequenza cassette holder (Thermo Scientific 73310017). 500µL of 2N HCl was added to
the slides and incubated for 20 mins at room temperature. Slides were then washed twice
with 0.1M Na2B4O7 pH 8.5 for 5 mins per wash. Slides were then put into a coplin jar
containing 10mM sodium citrate pH 6 and microwaved for 10 mins on low power level,
followed by a 20 min incubation at room temperature. Slides were washed again with
PBS and reinserted into the Shadon Sequenza holder (Thermo Scientific 73310017).
Slides were then washed twice with PBS containing 0.3% Triton-X. Anti-BrdU antibody
(BD, 347580) was diluted 1 in 50 in PBS-0.3% Triton-X and incubated on slides
overnight. The next day slides were washed three times with PBS-0.3% Triton-X then
secondary anti-mouse fluorescein (Vector, FI-2000) was added at a dilution of 1 in 800 in
PBS-0.3% Triton-X. Slides were then incubated in secondary for 1h in the dark. Slides
were washed 3 times in PBS-0.3% Triton-X then counterstained with DAPI for 5 mins in
the dark. Finally, slides were washed twice with PBS-0.3% Triton-X, twice with PBS,
mounted with Slowfade (Thermo Scienfic S36937) and sealed.
TUNEL staining was carried out according to manufactures instructions using In
Situ Cell Death Detection Kit (Roche, 1168479510). Briefly, cells were rehydrated with
PBS then permeabilized with PBS-0.3% Triton-X for 2 mins on ice then incubated for 1
hour with TUNEL reagent. After incubation slides were washed 3 times with PBS,
counterstained with DAPI for 5 mins followed by 2 washes with PBS-0.3% Triton-X and
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2 washes with PBS. Slides were then mounted with Slowfade (Thermo S36937) and
sealed.
Images were acquired using a Zeiss Axioskop 40 microscope and Spot flex
camera, and quantified using velocity image analysis software. (Perkin Elmer)

2.3.9

CDK2 Kinase activity assays.

Nuclear extracts were spun down at 14000 rpm for 30 mins to separate protein from
cellular debris. 250µg of protein from each sample was precleared for 1 hour using
Dynabeads rotating at 4°C. Samples were then split in half and incubated for an hour
with Dynabeads prebound with either IgG or anti-CDK2 (Millipore). Complexes were
then washed twice with IP wash buffer (10mM Tris pH 7.5, 200mM NaCl, 1.5mM
MgCl2, 2mM EDTA, 0.1% NP-40) and twice with kinase buffer (50mM Tris pH 7.5,
10mM MgCl2, 1mM DTT) and resuspended in 49µl of kinase buffer containing 4µg of
recombinant histone H1 (Santa Cruz). 10µCi of 32P radio-labelled ATP was incubated
with immunoprecipitates for 20 mins at 30°C, followed by boiling in SDS-PAGE buffer
to stop the reaction. Samples were then run out on a 15% gel, stained with Coomassie to
check for loading then dried and exposed to a phosphosensitive plate to determine 32P
incorporation.

2.4
2.4.1

Results
Post-translational stabilization of p27 in Rb1G/G fibroblasts
during quiescence.

Our previously published analysis of Rb1G/G primary fibroblasts and mice
indicates that loss of pRB-E2F repression fails to bypass cell cycle exit signals 30. Figure
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2.1 shows an example of a serum starvation arrest in which wild type, Rb1G/G, and knock
out cells were serum starved for 60 hours. Under these culture conditions wild type and
Rb1G/G cells reduce BrdU incorporation equivalently, while Rb1-/- cells are defective
(Figure 2.1A). However, analysis of mRNA levels of common E2F target genes shows
that Rb1G/G displays a similar defect in repression as Rb1-/- (Figure 2.1B). Importantly,
while cell cycle exit is normal in this scenario, pRB’s well studied role for restraining
E2F activation during cell cycle entry following serum stimulation is compromised in
Rb1G/G cells, and they enter the cell cycle with similar kinetics as knock out controls
(Figure 2.1C). Consistent with these findings, the R461E and K542E mutations encoded
by the Rb1G allele prevent stable interactions with E2Fs. We used immunoprecipitation
and western blot assays to evaluate pRB-E2F3 interactions in serum starved cells and
these reveal a robust defect (Figure 2.1D)30. Since Rb1G/G cells are functional for cell
cycle arrest in assays where Rb1-/- cells are not 30, we searched for parallel growth control
mechanisms to pRB-E2F repression that are pRB dependent. Building on previous
findings of p27 stabilization in cancer cells and Rb1-/- MEFs, we sought to determine if
this same effect was seen in our mutant Rb1G/G cells. Following serum deprivation of
asynchronously proliferating cultures, Rb1G/G MEFs demonstrated a modest increase in
p27 protein levels coincident with G1 arrest (Figure 2.1E). Importantly, p27 mRNA
levels quantitated by qRT-PCR remain the same as wild-type cells during serum
deprivation, indicating that the change observed is likely due to a post-translational effect
(Figure 2.1F). This finding is consistent with the post-translational stabilization of p27
observed in Saos2 cells induced to arrest following expression of E2F binding deficient
mutants of pRB 27. The increased p27 in response to loss of E2F regulation may be
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Figure 2.1: Increased expression of p27 in serum starved Rb1G/G MEFs.
(A) Fibroblast cells of the indicated genotypes were serum starved for 60 hours, pulselabelled with BrdU for 2 hours, followed by staining for BrdU incorporation. The
proportion of cells incorporating BrdU was determined by flow cytometry. (B)
Fibroblasts were serum starved as in A and the relative mRNA levels of the indicated
genes was determined. (C) Following serum starvation for 60 hours, cells were restimulated to enter the cell cycle. Cultures were pulse labeled with BrdU and harvested
at the indicated time points and analyzed by flow cytometry. (D) Whole cell extracts
were prepared from serum starved wild type and Rb1G/G MEFs. Western blots were
performed to assess relative expression of pRB and E2F3. Anti-E2F3
immunoprecipitations were blotted for pRB. (E) Immunoblotting of nuclear extracts
isolated from serum deprived MEFs using antibodies raised against p27 and Histone H3.
(F) Real-time quantitative PCR using primers to detect Cdkn1b. Values are presented
relative to GAPDH. All error bars represent one standard deviation from the mean. *
indicates a significant difference from the wild type control using a t-test, p<0.05.
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related to the ability of Rb1G/G MEFs to maintain proliferative control despite defective
E2F binding.

2.4.2

Rb1G/G; Cdkn1b-/- mice are highly cancer prone.
To determine if p27 expression in Rb1G/G cells is responsible for the maintenance

of cell cycle control, we crossed Rb1G/G mice with p27 deficient (Cdkn1b-/-) animals.
Compound mutant mice display similar viability at weaning as the Rb1G/G genotype alone
and without obvious anatomical defects, suggesting the combination of Rb1G/G and
Cdkn1b-/- deficiency is no different than either single mutant alone (Figure 2.2A, Table
2.1)30. While double mutant Rb1G/G; Cdkn1b-/- mice show normal development, we aged
cohorts of double and single mutant mice and discovered that Rb1G/G; Cdkn1b-/- mice
succumb to pituitary tumors with an average tumor free survival of 214 days (Figure
2.2B). Necropsies of these mice revealed pituitary tumor masses characteristic of Rb1
deficient animals (Figure 2.2C). By comparison, neither Rb1G/G nor Cdkn1b-/- mice
displayed cancer susceptibility (Figure 2.2BC), and this is consistent with prior reports
of mixed 129/B6 Cdkn1b-/- mice 35. Interestingly, Rb1G/+; Cdkn1b-/- mice also succumb
to pituitary tumor formation with a delayed latency compared to double mutants and with
approximately 75% penetrance (Figure 2.2BC). PCR genotype analysis revealed that
loss of the wild type copy of Rb1 is ubiquitous in these tumors (Figure 2.2D). The
Rb1G/+; Cdkn1b-/- tumor phenotype is highly reminiscent of Rb1+/-; Cdkn1b-/- tumors in
terms of latency and the requirement for loss of heterozygosity of Rb1 35. Based on this
observation, the Rb1G allele appears to be the functional equivalent of an Rb1 null allele
when combined with p27 deficiency in this context. These genetic data also imply that
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Figure 2.2: Cancer susceptibility in Rb1G/G; Cdkn1b-/- mice.
(A) Picture of young adult double mutant Rb1G/G; Cdkn1b-/- mouse. (B) Kaplan-Meyer
analysis of tumor-free survival for mice of the indicated genotypes. Mice were
monitored until natural endpoint and those having tumors are shown. Rb1G/G; Cdkn1b-/-,
Rb1G/+; Cdkn1b-/- and Rb1+/- are significantly different from one another and from all
single mutant controls using Log rank test (P<0.05). (C) Macroscopic images of
pituitaries of mice from the indicated genotypes at necropsy. Scale bars are 1cm. (D)
Genotyping of tumor and tail DNA isolated from Rb1G/+; Cdkn1b-/- mice demonstrating
loss of heterozygosity in the tumor tissue.
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p27 function is required for pRB dependent tumor suppression when pRB is defective for
E2F binding, and that pRB-E2F control is critical in the absence of p27.

2.4.3

Compound mutant Rb1G/G; Cdkn1b-/- MEFs enter quiescence
following serum deprivation.
The normal development of double mutant animals suggests that pRB-mediated

repression of E2Fs, as well as deficiency for p27, are dispensable for a variety of cell
cycle exit decisions that occur as part of a normal mammalian developmental program.
However, emergence of pituitary adenocarcinomas indicates that this combination is
important in some context for the mitigation of tumorigenesis. We therefore sought to
understand if specific cell cycle control functions are lost in Rb1G/G; Cdkn1b-/- cells.
Since both pRB and p27 are implicated in quiescence, we assessed their separate and
combined contributions to serum deprivation-induced arrest 2. Asynchronously
proliferating cultures of primary fibroblasts for each of wild type, Rb1G/G, Cdkn1b-/-,
double mutant Rb1G/G; Cdkn1b-/-, and Rb1-/- were analyzed for their proliferative state by
BrdU labeling and flow cytometry. Figure 2.3A shows baseline levels of BrdU
incorporation for each genotype while actively proliferating, and it shows Rb1G/G;
Cdkn1b-/-, and Rb1-/- have statistically elevated BrdU incorporation levels. Cells were
subsequently washed and transferred to 0.1% serum to induce arrest for 60 hours before
pulse labeling with BrdU. While asynchronously cycling double mutant Rb1G/G; Cdkn1b/-

MEFs exhibit an increase of cells in S-phase while proliferating, these cells could

restrict S-phase entry following serum deprivation, to a level equivalent to that of wild
type fibroblasts (Figure 2.3B). Importantly, the incomplete response in Rb1-/- cells
indicates that this is a pRB dependent process that Rb1G/G; Cdkn1b-/- cells are capable of

61

Figure 2.3: Compound mutant Rb1G/G; Cdkn1b-/- MEFs enter quiescence.
(A) Asynchronously growing MEFs were pulsed-labelled with BrdU for two hours
followed by staining for BrdU incorporation and analysis by flow cytometry. (B)
Proliferating cells were serum deprived for 60 hours and pulse-labelled with BrdU for
two hours followed by staining for BrdU incorporation and flow cytometry. All error
bars represent one standard deviation from the mean. * indicates a significant difference
from the wild type control using a t-test, p<0.05. (C) CDK2 kinase activity was
determined by incubation of immunoprecipitated CDK2 complexes isolated from the
indicated genotypes of cells under asynchronous growth conditions (AS), or serum
starved conditions (SS). Proteins isolated by immunoprecipitation with anti-CDK2
antibodies (IP) or control (IgG) were mixed with recombinant histone H1 and γ- 32P-ATP,
incubated, and resolved by gel electrophoresis and exposed to a phosphosensitive plate.
Coomassie staining of the recombinant histone H1 serves as a loading control.
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executing. Similarly, analysis of CDK2 activity by IP-kinase assays reveals that single
mutant Rb1G/G and Cdkn1b-/- cells were also capable of inhibiting CDK2 kinase activity
(Figure 2.3C), as were double mutant Rb1G/G; Cdkn1b-/- MEFs. Some residual CDK2
activity was also observed in the Rb1-/- cells following serum deprivation reflecting the
defect in G1 arrest observed in Rb1-/- MEFs (Figure 2.3C). Maintenance of quiescence
and CDK2 inhibition in double mutant Rb1G/G; Cdkn1b-/- MEFs agrees with the
developmental milestones observed in Rb1G/G; Cdkn1b-/- mice, as quiescence induction is
a component of normal development 36.

2.4.4

Compound mutant Rb1G/G; Cdkn1b-/- cells display defective
cell cycle control in response to DNA damage.
The detection of malignancies later in life in Rb1G/G; Cdkn1b-/- mice likely

indicates that additional mutations occur prior to tumorigenesis. Therefore, we next
looked at the ability of single and double mutant Rb1G/G; Cdkn1b-/- MEFs to arrest the
cell cycle in response to DNA damage, as a defect in this response could facilitate the
acquisition of new mutations. We subjected asynchronously proliferating cells to three
different DNA damaging agents; gamma irradiation (IR), cisplatin, and hydrogen
peroxide and pulse labelled cells with BrdU 48 hours later. The percentage of BrdU
positive cells was then determined by flow cytometry (Figure 2.4A). With each
treatment, double mutant Rb1G/G; Cdkn1b-/- and Rb1-/- cells failed to block BrdU
incorporation. Interestingly, some single mutants showed modest defects in their
response to Cisplatin and hydrogen peroxide (Figure 2.4A). However, analysis of DNA
content by propidium iodide staining following IR, showed that both double mutant
Rb1G/G; Cdkn1b-/- and Rb1-/-
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Figure 2.4: Mutant Rb1G/G; Cdkn1b-/- MEFs display defective cell cycle control in
response to DNA damage.
(A) MEFs were treated with the indicated dose of DNA damaging agents. 48 hours later
cells were pulsed with BrdU, stained and analyzed by flow cytometry. All error bars
represent one standard deviation from the mean. * indicates a significant difference from
the wild type control using a t-test, P<0.05. (B) Propidium iodide (PI) staining of MEFs
treated with 15Gy of ionization radiation showing DNA content of cells. Red boxes
outline area of >4N DNA content with the number representing the percentage of cells in
that box. (C) Kinase assays were performed using CDK2 kinases isolated from
asynchronously growing (AS) or following treatment with ionizing radiation (γIR).
Kinase activity was determined by incubation of immunoprecipitated CDK2 complexes
with recombinant histone H1 with and γ-32P-ATP followed by gel electrophoresis and
exposure to a phosphosensitive plate. Coomassie staining of recombinant histone H1
serves as a loading control.

64

MEFs exhibit a high proportion of cells with 8N DNA content, implying a strong defect
in the regulation of DNA replication following damage (Figure 2.4B). This suggests that
loss of both pRB-E2F binding and p27 together results in a defective DNA damage
checkpoint leading to endoreduplication in a manner that is very similar to complete Rb1
deficiency. We also tested CDK2 activity from extracts of IR treated cells using an IPkinase assay. Once again, Rb1G/G and Cdkn1b-/- single mutant MEFs could reduce CDK2
kinase activity down to background levels, whereas double mutant Rb1G/G; Cdkn1b-/- and
Rb1-/- MEFs were only able to partially restrict CDK2 kinase activity mirroring the result
seen by BrdU incorporation analysis (Figure 2.4C). The failure of double mutant
Rb1G/G; Cdkn1b-/- MEFs to arrest in response to DNA damage provides a possible
framework to explain the eventual development of pituitary adenocarcinomas in older
mice. Therefore, in the context of DNA damage, Rb1G/G; Cdkn1b-/- animals may be
unable to respond appropriately to the insult, allowing for the development of further
mutations and the clonal expansion tumorigenic cells.

2.4.5

Compound mutant Rb1G/G; Cdkn1b-/- fibroblasts undergo
rapid immortalization in culture.
We also modeled the acquisition of cancer enabling mutations over time using a

3T3 immortalization assay to assess the different Rb1 and Cdkn1b mutant genotypes. By
passaging primary MEFs in a 3T3 protocol we were able to subject them to long-term
oxidative stress 37, its resultant DNA damage 37, and determine genotype specific
responses. We categorized entry into senescence in this assay as the first passage that
displays a negative population increase. Furthermore, we categorized immortalization as
the first passage where positive population increases resumed and continued

65

uninterrupted for the remainder of the 20 passage experiment. From this analysis, we
note that all attempts to immortalize Rb1G/G; Cdkn1b-/- and Rb1-/- MEFs were successful
(Figure 2.5A), whereas at least half of single mutant or wild type controls entered
senescence and never resumed proliferation. All wild type, single mutant, and Rb1G/G;
Cdkn1b-/- double mutant cells entered senescence as evidenced by negative growth trends
(Figure 2.5B-F). In this assay, only Rb1-/- cells spontaneously immortalized without
entering senescence (Figure 2.5F). Notably, double mutant Rb1G/G; Cdkn1b-/- cells
demonstrated a longer period of positive growth compared to single mutants (Figure
2.5E), and they spent fewer passages in senescence before resuming continual expansion.
A similar profile of brief arrest before rapid expansion was exhibited by most Rb1-/- cells
cultures (Figure 2.5F), and this further emphasizes the similarity between the Rb1G/G;
Cdkn1b-/- and Rb1-/- genotypes in this assay. This result demonstrates that cells
containing mutations to abolish pRB-E2F repression and loss of p27, are poised to
immortalize and this property is consistent with their inability to arrest the cell cycle
following DNA damage.

2.4.6

Compound mutant Rb1G/G; Cdkn1b-/- cells in the embryonic
intermediate pituitary demonstrate radio resistant DNA
synthesis.
Given the propensity of Rb1G/G; Cdkn1b-/- mice to develop pituitary tumors as

demonstrated in this report, and the long history of Rb1 null alleles to predispose mice to
this tumor type, we sought to assess cell cycle regulation in this tissue. As the
intermediate lobe of the pituitary gland gives rise to the adenocarcinomas previously
reported in Rb1 mutant mice 38,39, we chose to investigate the DNA damage response
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Figure 2.5: Rb1G/G; Cdkn1b-/- MEFs undergo rapid immortalization in response to
oxidative stress.
(A) Percent of cultures that immortalized within 20 passages of 3T3 culture.
Immortalization was defined as continued positive population growth following a decline
in cell number at intermediate passages. (B-F) Population growth of MEFs of the
indicated genotypes was plotted against passage number. Cells were plated at a density
of 1x106 cells per 10 cm plate, and they were re-seeded at the same density every 3 days.
Population increase was calculated according to the formula:
(Log10(recovered/seeded))/Log102 and plotted cumulatively over 20 passages, or until no
viable cells were left in the culture.
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specifically in these cells. To analyze acute response to DNA damage in the pituitary,
embryos at 13.5 days of gestation were used as the peak proliferation of the pituitary
occurs at this time and postnatal proliferation is largely undetectable 40. Pregnant
mothers were exposed to a dose of 10Gy of ionizing radiation four hours prior to
injection with BrdU and sacrificed two hours later. Tissue sections of embryos were cut
to expose the developing pituitary and sections were stained to detect BrdU (Figure
2.6A). Wild type, as well as single mutant Rb1G/G and Cdkn1b-/- embryos, displayed a
robust reduction in BrdU incorporation following DNA damage, as determined by
counting BrdU positive nuclei in the intermediate lobe of the pituitary (Figure 2.6B).
Similar to our findings in cell culture both Rb1G/G; Cdkn1b-/- and Rb1-/- embryos did not
display a significant reduction of BrdU incorporation following irradiation (Figure 2.6B).
TUNEL staining of parallel sections was performed to quantitate double stranded DNA
breaks and reveals similar levels of damage among all genotypes (Figure 2.6C). This
outcome indicates that the cell cycle arrest defect following DNA damage in double
mutant Rb1G/G; Cdkn1b-/- cells is evident in both cell culture and in vivo settings, and it
occurs in the cell population that eventually gives rise to the tumor phenotype seen in
these mice. Thus, the regulation of E2Fs by pRB as well as CDK control via p27 are
each individually dispensable for cell cycle control, simultaneous loss of both leads to an
insensitivity to DNA damage signalling and a predisposition to cancer.

2.5

Discussion

Our findings support the existence of a link between pRB-mediated growth
control and CDK regulation that is independent of pRB-E2F control of transcription. The
similar defect in DNA damage induced growth arrest between Rb1G/G; Cdkn1b-/- and
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Figure 2.6: Double mutant Rb1G/G Cdkn1b-/- embryonic pituitaries exhibit radio
resistant DNA synthesis.
(A) Representative images of E13.5 pituitaries stained for BrdU from control or
irradiated embryos. The intermediate lobe of the pituitary is outlined in dashed white
lines. (B) The of percentage of BrdU positive cells in the intermediate lobe of the
pituitary was determined from the indicated genotypes of mice from control or irradiated
groups. All error bars represent one standard deviation from the mean. * indicates a
significant difference from the wild type control using a t-test, P<0.05. (C) Tissue
sections were stained with TUNEL and positive cells within the intermediate lobe of the
pituitary were quantitated for in the indicated genotypes either with or without
irradiation. All error bars represent one standard deviation from the mean and there are
no significant differences amongst the treated groups.
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Rb1-/- implies that E2F independent growth control by pRB is dependent on CDK
regulation by p27. In addition, we find that defective E2F binding by pRB, or loss of
p27, are individually tolerated in most arrest assays suggesting their functions are
somewhat interchangeable. Lastly, cancer incidence and latency is very similar between
our Rb1G/+; Cdkn1b-/- mice and previously published Rb1+/-; Cdkn1b-/- mice 35, and this
suggests that in the absence of p27, the Rb1G allele is approximately equivalent to an Rb1
null. Collectively, these data point to a strong interdependence of CDK and E2F
regulation.
Previous studies of endogenous pRB function in mice have typically relied on
knock out alleles. This approach to mechanistic understanding is constrained by several
limitations that are overcome in our targeted knock in approach. First, other pRB family
members, p107 and p130, increase in expression in pRB’s absence 3,41. Additionally,
pRB is reported to interact with over one hundred proteins 42, so complete loss of pRB
disrupts all of these binding partners, obscuring the roles of individual interactions. For
these reasons, our Rb1G/G model specifically mitigates these problems allowing us to
demonstrate a role for pRb-E2F interactions in vivo in tumor suppression. Surprisingly,
these studies and our previous report of these mice, reveal that loss of pRB-E2F
transcriptional repression functions in parallel with p27 in growth control and tumor
suppression 30.
We have found that disruption of pRB-E2F interactions act synergistically with
p27 deletion to bring about a loss of cell cycle control. The degree of disruption is
similar to complete pRB knock out and this implies that p27 may lie downstream of pRB
in an E2F independent growth arrest pathway. A number of previous reports have
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identified a link between pRB and p27 as a means of crosstalk between the RB pathway
and the CDK regulatory pathway 25,26. pRB has been shown to interact with Skp2 as well
as the APCCdh1 complex25,26. These interactions allow pRB to reduce available Skp2
either through facilitation of Skp2 ubiquitination by APC Cdh1 or through Skp2
sequestration. Ultimately, these interactions stabilize p27 expression and block CDK
activity independent of pRB-E2F transcriptional repression. However, each of these
reports relies on over expression of pRB as the growth arresting stimulus, leaving in
question the physiological circumstance where this mechanism works. We think this
report offers proof of principle for a pRB-p27 regulatory axis, in addition to showing that
it functions in DNA damage induced arrest, its inactivation renders mice cancer prone.
This argues that the pRB-p27 connection is critical to what makes pRB a tumor
suppressor.
The interplay between pRB and p27 identified in this study may also provide
important insight into the utilization of targeted therapies aiming to restore cell cycle
control. A number of CDK4/6 inhibitors have been developed in attempts to re-establish
the G1 checkpoint in cancer cells43-45. Since CDK4/6 inhibition is known to arrest
proliferation only when pRB is functional, these inhibitors are generally given to patients
with pRB positive cancers. However, pRB status alone does not indicate the
effectiveness of these treatments 46. Our analysis of G1 checkpoint control may provide
some insight into ways to maximize the effectiveness of these treatments. We suggest
that reactivation of the pRB pathway by CDK4/6 inhibitors may be more effective in
cancers with inherently high p27 expression, or whose p27 stabilization pathways remain
active.
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Overall, our findings reveal a role for pRB in DNA damage induced cell cycle arrest,
beyond repression of E2F transcriptional activity that utilizes p27 and CDK inhibition.
Furthermore, our work suggests a functional context for the regulation of p27 by pRB
that has been elusive.

2.6
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Chapter 3

3

Multiple molecular interactions redundantly contribute to
RB-mediated cell cycle control.
3.1

Abstract

The G1-S phase transition is critical to maintaining proliferative control and
preventing carcinogenesis. The retinoblastoma tumor suppressor (pRB) is a key regulator
of this step in the cell cycle. Here we use a structure-function approach to evaluate the
contributions of multiple protein interaction surfaces on pRB towards cell cycle
regulation. SAOS2 cell cycle arrest assays showed that disruption of three separate
binding surfaces were necessary to inhibit pRB-mediated cell cycle control. Surprisingly,
mutation of some interaction surfaces had no effect on their own. Rather, they only
contributed to cell cycle arrest in the absence of other pRB dependent arrest functions.
Specifically, our data shows that pRB-E2F interactions are competitive with pRB-CDH1
interactions, implying that interchangeable growth arrest functions underlie pRB’s ability
to block proliferation. Additionally, disruption of similar cell cycle control mechanisms
in genetically modified mutant mice results in ectopic DNA synthesis in the liver. Our
work demonstrates that pRB utilizes a network of mechanisms to prevent cell cycle entry.
This has important implications for the use of new CDK4/6 inhibitors that aim to activate
this proliferative control network.

3.2

Introduction

Uninhibited cellular division is a feature of cancer cells. As such, pathways that
regulate proliferation are typically disrupted in human cancer 1. At a molecular level, the
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cell division cycle is frequently controlled by decisions made in the G1 phase 2. Once
through this phase, the cell is committed to DNA replication and ultimately completion of
cell division. The retinoblastoma gene product (pRB) is a key regulator of the restriction
point that is responsible for controlling S-phase entry 3. The best known function of pRB
is the repression of E2F transcription factor activity 4. RB performs this function by
directly binding the transactivation domain of E2Fs, preventing the recruitment of
transcriptional activators to influence gene transcription 4. In addition, pRB can recruit
chromatin regulating enzymes, such as histone deacetylases, to assist in transcriptional
repression 5. This blocks gene expression that is necessary for DNA synthesis and cell
cycle entry 2. In the presence of mitogens Cyclin dependent kinases phosphorylate pRB,
changing its conformation and releasing E2Fs 6. Free E2Fs are then able to stimulate
transcription and S-phase progression. While this model describes cell cycle entry quite
accurately, the role for the same molecular interactions between pRB and E2Fs in cell
cycle exit is less clear as pRB dependent arrest can occur much faster than E2F
repression 7.
The minimal interaction domain that mediates stable E2F binding to pRB is the large
pocket, and this fragment is also the minimal growth suppressing domain 8,9. The large
pocket is composed of three regions called A, B, and C 3. The A and B domains of pRB
form the pocket in which the transactivation domain of E2Fs bind 10,11. In addition, pRB
interacts with a number of chromatin regulators, including HDAC containing complexes,
through a well conserved interaction site on the B box of pRB known as the LxCxE
binding cleft 5. This binding site is well defined for its ability to contact the LxCxE motif
in viral oncoproteins 12. Simultaneous interactions between E2Fs, pRB, and chromatin
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regulators through LxCxE interactions form the basis of active transcriptional repression
through E2Fs. The C-terminus of pRB is largely unstructured and serves as a contact
point for numerous protein interactions 3,13. It is required for stable interaction with E2FDP dimers 14, as well as a unique interaction with the marked box domain of E2F1 15.
Analysis of the large pocket of pRB has contributed to our knowledge of E2Fs in cell
cycle control. However, there is little to reconcile how multiple competing protein
interactions through this domain contribute to pRB’s overall influence on cell
proliferation.
Genetic ablation of RB causes defects in cell proliferation control in tissues and in
primary cell culture experiments 16,17. However, early studies of pRB-mediated cell cycle
regulation exploited the RB null SAOS2 osteosarcoma cell line 8,9,18. RB expression in
these cells leads to a robust accumulation of 2N DNA content, indicating a G1 arrest 19.
These studies looked at a variety of mutant versions of pRB in which strong cancer
derived mutations were functionless, but low penetrance RB mutations retained the
ability to at least partially restrict cell cycle entry 8,9,20,21. Surprisingly, the low penetrance
mutation R661W was defective for E2F binding, but retained the ability to inhibit cell
cycle entry 20-22. More recently, a number of studies have shown that the R661W mutant
can regulate Cyclin dependent kinase activity through p27, independent of E2F
transcriptional control 7,23. Importantly, these studies established that the LxCxE binding
cleft and C domains within the large pocket also mediate interactions with the anaphase
promoting complex and Skp2 to stabilize p27 expression 7,24. Surprisingly, a unified
model of how E2F dependent and independent proliferative control mechanisms interact
has yet to emerge.
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To understand the importance of different protein interaction points in the RB large
pocket, targeted mutations to disrupt the LxCxE binding cleft 25-28, the canonical E2F
binding site 29,30, and pRB’s unique interaction with E2F1 in the C-terminus 31,32, have
been generated in mice. Analysis of proliferation in cells and tissues from these mutant
animals suggests that individual protein interactions play context specific roles. For
example, LxCxE binding cleft mutant mice (called Rb1L, or Rb1NF) are viable with hyper
proliferation largely limited to mammary ductal epithelium, that is likely due to
unresponsiveness to growth inhibitory signals from TGF-β 33. Importantly, these mice are
not spontaneously cancer prone 27,34, and they are capable of blocking E2F transcription
under several physiological circumstances 35. However, repression of E2F targets is
diminished following DNA damage, and the ability of these cells to enter senescence is
compromised 35,36. Furthermore, mutagen treatment induces cancer in these mice under
conditions where E2F repression fails 26. Disruption of pRB’s unique E2F1 interaction in
mice (called Rb1S) shows no detectable change in proliferative control in tissues or
isolated cells 32. Lastly, mutational disruption of pRB-E2F interactions in Rb1G/G mice
results in cells with accelerated entry into the cell cycle, but normal cell cycle exit 29,30.
Remarkably, this mutation does not predispose mice to cancer 29, however, disruption of
this interaction in combination with p27 deficiency deregulates cell cycle arrest functions
and these mice are highly cancer prone 30. This result is also provocative because the cell
cycle arrest defects in Rb1G/G; p27 deficient compound mutants aren’t found in either
single mutant strain alone. These data suggest that pRB dependent cell cycle arrest may
depend on a complex network of proliferative control signals such that loss of individual
functions have limited effect on their own. This concept is underscored by the fact that no
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targeted knock in strain recapitulates the complete proliferative control and cancer
susceptibility phenotypes of Rb1-/- mice. In this manuscript, we aimed to eliminate
individual binding surfaces in the pRB large pocket to determine the extent that each
contributes to cell cycle control alone and in combinations using SAOS2 arrest as a read
out. Here, we demonstrate that multiple individual binding surfaces in the large pocket
contribute to pRB-mediated cell cycle control in cell culture, and provide proof of
principle that this network functions endogenously to regulate DNA replication in the
liver.

3.3
3.3.1

Materials and Methods
GST pulldowns and western blotting

C33A cells were transfected with either HA-E2F1-3 (along with DP1), myc
tagged CDH1 or pRB expression plasmids under the control of CMV promoters using
standard calcium phosphate precipitation techniques. Forty hours after transfection cells
were washed and collected in GSE buffer (20mM Tris, pH 7.5, 420 mM NaCl, 1.5 mM
MgCl2, 0.2mM EDTA, 25% glycerol, 5 µg/ml leupeptin, 5 µg/ml aprotinin, 0.1 mM
Na3VO4, 0.5 mM NaF, and 1 mM DTT) and frozen at -80°C. Cell extracts were
centrifuged and the supernatant was diluted 2-fold in low salt GSE (20mM Tris, pH 7.5,
1.5 mM MgCl2, 0.2mM EDTA, 25 mM DTT, 0.1% NP-40) and combined with
glutathione beads and recombinant fusion proteins. GST-RB large pocket (amino acids
379-928) and GST-HPV-E7 recombinant proteins were expressed and purified as
previously described 29. Beads were then washed twice with low salt GSE, boiled in SDSsample buffer, resolved by SDS-PAGE, and western blotted. HA-tagged proteins were
detected using anti-HA 3F10 (Roche), myc-tagged CDH1 was detected using monoclonal
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antibody 9E11, and pRB was detected with G3-245 (BD Pharmagen). To test pRB
stability, cells transfected with CMV expressed pRB were treated with 100µg/mL
cycloheximide for 24 hours. Extracts were prepared in GSE buffer every three hours up
to 15 hours. Extracts were spun down and western blotted for pRB.

3.3.2

SAOS2 cell cycle arrest assays
SAOS2 cells were transfected and harvested as previously described 37. Briefly

106 cells were plated in 6cm dishes and transfected with 0.15µg of CMV-pRB, 1µg of
CMV-CD20 and 3.85µg of CMV-β-gal, or 1µg of CMV-CD20 and 4µg of CMV-β-gal as
a negative control, using X-tremeGENE transfection reagent (Roche). Cells were replated onto 10cm dishes 24 hours after transfection, and harvested 48 hours later. Cells
were then stained with a fluorescein conjugated anti-CD20 antibody to mark successfully
transfected cells, as well as with propidium iodide (PI) to determine their DNA content.
Flow cytometry was then performed to identify the percentage of CD20 positive cells
with 2N DNA content as a measure of G1. In experiments expressing cell cycle arrest as
percent change in G1, arrest data was scaled using CMV-pRB and CMV-β-gal as
standards for maximal increase and unchanged G1 content allowing comparisons
between different batches of experiments.

3.3.3

Animal housing, dissection and histology
All animals were housed and handled as approved by the Canadian Council on

Animal Care. Mice were sacrificed at 8 weeks of age, dissected, and livers were
processed for downstream applications. For histology, livers were fixed in formalin for
72 hours followed by 72 hours in PBS before being stored in 70% ethanol. Livers were
then embedded in paraffin and five micron sections were cut and stained with
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Hematoxylin and Eosin. Images were captured on a Zeiss Axioskop 40 microscope and
Spot Flex camera, and nuclear area in the livers was calculated using EyeImage software
(Empix Imaging, Mississauga, Ontario, Canada).

3.3.4

Ploidy analysis of adult livers
A small piece of frozen liver was added to buffer A (25mM Tris pH 7.5, 50mM

KCl, 2mM MgCl2, 1mM EDTA, 1mM PMSF). Tissue was ground on ice with a
mechanical tissue grinder. Tissue was then homogenized using a 1mL dounce
homogenizer and tight pestle. Nuclei were centrifuged at 12000xg, then washed in buffer
A and centrifuged. The pellet was then resuspended in Propidium Iodide solution
(0.5mg/mL PI, 0.1% NP-40, 0.1% sodium citrate, 40µg/mL RNase A in PBS). Samples
were then analyzed by flow cytometry using standard methods to quantitate DNA
content.

3.3.5

RNA isolation and E2F target gene quantification.
RNA from livers was isolated using an RNeasy fibrous tissue kit (Invitrogen).

Expression levels of the E2F target genes, Pcna, Ccne1 (Cyclin E1), Ccna2 (Cyclin A2),
Tyms (thymidylate synthase), Mcm3, and Rbl1 (p107), were determined using the
Quantigene Plex 2.0 reagent system from Affymetrix (Santa Clara, CA) and a
BioPlex200 multiplex analysis system as previously reported 38. Expression levels were
normalized to the expression of β-actin.

3.3.6

BrdU staining of tissue sections.

To analyze DNA replication, mice were injected with 200L of 16µg/mL BrdU
(Sigma) in their peritoneal cavity 2 hours before sacrifice. Livers were then isolated,
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fixed in formalin, embedded, and sectioned according as above. Sections were
deparaffinized and rehydrated using a series of xylene and ethanol washes. The sections
were brought to a boil in sodium citrate buffer and then maintained at 95°C for 10 min.
The cooled sections were rinsed in water three times for 5 minutes, and then rinsed in
PBS for 5 minutes. The sections were blocked in phosphate buffered saline (PBS)
supplemented with 2.5% horse serum and 0.3% Triton X-100 for 1 hour. The sections
were then incubated with anti-BrdU antibodies (BD-Biosciences) in blocking buffer
overnight at 4°C and rinsed in PBS three times for 5 minutes each time. The slides were
incubated with horse anti-mouse immunoglobulin G-fluorescein isothiocyanate (Vector)
for 1h and rinsed in PBS. The slides were then mounted with Vectashield plus DAPI
(Vector). Fluorescent images were captured on a Zeiss Axioskop40 microscope and Spot
Flex camera and colored using EyeImage software (Empix Imaging, Mississauga,
Ontario, Canada), or a similar system.

3.4
3.4.1

Results
A cell culture assay demonstrates molecular redundancy of
RB functions in proliferative control.

Tumor suppression by the retinoblastoma protein has typically been associated
with its ability to block cell cycle progression and repress E2F transcription factors 4.
However, defective E2F binding by pRB has been shown to have modest effects on
proliferative control in SAOS2 cell culture experiments 15,20-22, and gene targeted mouse
models 29,30. In an attempt to describe the molecular interactions necessary for pRBmediated cell cycle arrest we investigated forms of pRB that were individually mutated at
each of three distinct binding surfaces in the large pocket; the general E2F binding site
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Figure 3.1: Interaction domains located in the large pocket of pRB and substitutions
used in this study.
(A) Linear diagrams of open reading frames for the indicated proteins highlighting the
regions that mediate interactions with pRB. Note pRB can bind E2F1-4 through the
transactivation domain in the C-terminus of E2Fs known as the ‘general’ interaction.
Alternatively, pRB can also bind the marked box domain of E2F1 through its C-terminal
domain, termed the pRB-E2F1 ‘specific’ interaction. (B) Locations of point mutations
within the pRB open reading frame used in this study. RB G refers to mutations that
disrupt the E2F general interaction, RBS is a mutation that disrupts the E2F1 specific
interaction. RBC and RBL both disrupt interactions through the LxCxE binding cleft. All
codon numbers correspond to the human sequence. The large pocket domain is amino
acids 379-928. (C) Diagram depicting the cell cycle control mechanisms that can be
influenced by the 3 pRB binding surface mutations used in this study.

84

(RBG), the E2F1 specific site (RBS), and the LxCxE binding cleft (using either the RB L or
RBC mutations). Figure 3.1A diagrams pRB protein interactions and shows the relevant
regions in each open reading frame that participate. Amino acid substitutions that are
demonstrated to disrupt these contacts are shown in Figure 3.1b 24,37,39,40, along with
single letter nomenclature for each allele (e.g. RBG). Lastly, the types of interactions
between pRB and E2Fs, or LxCxE motif proteins, are illustrated with the alleles that
disrupt them individually shown on the right, and the intended effect of a combined
mutant allele on the left (Figure 3.1C).
GST-tagged versions of the pRB large pocket (GST-RBLP, pRB amino acids
379-928) containing the 3 mutations described above, as well as the triple mutant, were
produced in bacteria. GST pulldowns were performed to test interaction defects predicted
to occur in these mutants (Figure 3.2A). RB deficient C33A lysates derived from
transfections with the indicated E2Fs, or CDH1 were produced and used in pulldown
experiments. As expected the RBG mutation disrupts binding of the activator E2Fs, E2F2
and E2F3. RBL disrupts the LxCxE binding cleft and is defective for binding the
anaphase promoting complex targeting subunit CDH1. Finally, since E2F1 can associate
with pRB through two qualitatively different interactions, the general site and the specific
site, binding is only lost following mutation of both sites in the triple mutant RB GSL. Full
length pRB constructs containing these mutations were then transfected into SAOS2 cells
to determine their effectiveness in causing a G1 cell cycle accumulation. As previously
shown, expression of wild-type pRB in SAOS2 cells lead to a build up of cells in G1 as
determined by propidium iodide staining and flow cytometry (Figure 3.2B)19. Expression
of the mutant constructs of pRB had various levels of effectiveness for
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Figure 3.2: Multiple point mutations are needed to overcome RB-mediated cell cycle
arrest.
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Figure 3.2: Multiple point mutations are needed to overcome RB-mediated cell cycle
arrest.
(A) GST-tagged RB large pocket proteins corresponding to the RB G, RBS, RBL, and
RBGSL mutant versions of pRB were produced and purified. These GST-fusions were
incubated with C33A extracts transfected with the indicated expression constructs. Bound
proteins were isolated by precipitation and identified by western blotting. (B) Constructs
containing full-length RB harboring the indicated mutations under the control of a CMV
promoter were transfected into SAOS2 cells along with a CD20 reporter. Cells were then
stained with propidium iodide and the percentage of cells in G1 were determined by
DNA content of CD20 positive cells. Bars indicate the mean of three separate
experiments, and error bars indicate one standard deviation from the mean. Letters
indicate groups that are significantly different from one another (ANOVA, Tukey test,
p<0.05). (C) Full length CMV-RB constructs were transfected into C33A cells and
extracts were incubated with recombinant HPV-E7. Bound proteins were isolated by
precipitation and western blotted to detect pRB. (D) Full length RBWT and RBGSC were
transfected into C33A cells prior to cycloheximide treatment (CHX). Extracts were
prepared over a 15 hour time course and stability was monitored by Western blotting. (E)
Constructs containing full-length RB harboring the various mutations, or combinations of
mutations, under the control of a CMV promoter were transfected into SAOS2 cells along
with a CD20 reporter. Cells were then stained with propidium iodide and the percentage
of cells in G1 were determined by DNA content of CD20 positive cells. Bars indicate the
mean of three separate experiments, and error bars indicate one standard deviation from
the mean. (F) Transfections and cell cycle analysis were performed as in B and E, except
the increase in G1 cells is shown as Change in % G1 (relative to β-Gal control). Letters
indicate groups that are significantly different from one another (ANOVA, Tukey test,
p<0.05).
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inducing a G1 cell cycle arrest (Figure 3.2B). Notably, the RBS mutation showed a
similar ability to block proliferation as wild-type RB (Figure 3.2B). By contrast,
disruption of the general binding pocket in the RBG mutant, or disruption of the LxCxE
binding cleft (RBL) resulted in a significant, but partial decrease in the percentage of cells
in the G1 phase of the cell cycle (Figure 3.2B). Importantly, no individual mutation can
completely disrupt RB function. However, when all three mutations were combined into
one pRB molecule (RBGSL), the ability of pRBGSL to induce a G1 arrest was not
statistically different from that of the β-Gal negative control (Figure 3.2B). As disruption
of the various interactions lead to an inability of pRB to bind to any of its LxCxE or E2F
interactors, we next aimed to confirm that combination mutations led to disruption of
these binding surfaces, as opposed to simply disrupting pRB structure or stability. To
address this possibility, we used the RBC mutation that retains the ability to associate
with HPV-E7, but has previously been shown to be defective for its interaction with
CDH1 24,37,39,40. Figure 3.2c demonstrates that both the RBC, and an RBGSC combination
could maintain RB-E7 interaction, suggesting this mutant combination retains it structure.
Furthermore, the stability of the RBGSC mutation was determined by expressing both
RBWT and RBGSC in C33A cells. Cells were then treated with cycloheximide and protein
was isolated over a period of 15 hours. Western blots confirmed that RB WT and RBGSC
have equal stability, further suggesting that these substitutions do not result in the
misfolding and hence pleiotropic loss of pRB function (Figure 3.2D). Finally, SAOS2
cell cycle arrest assays were performed using the RBC mutant alone or in double and
triple combinations (RBGC or RBGSC). As with the RBGSL mutant, the triple mutant
combination RBGSC was unable to increase the proportion of G1 cells beyond that of β-
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Gal controls (Figure 3.2E). In addition, SAOS2 cell cycle arrest following transfection
with the RBGC and RBGS double mutants diminished the ability to induce a G1 cell cycle
arrest beyond any single mutant, but was less detrimental than the RB GSC combination
(Figure 3.2F). These results demonstrate that pRB’s activity in this arrest assay can be
defined through loss of individual protein interactions.
The combination of RBG and RBL mutations in RBGSL is more severe than either
alone (Figure 3.2B). It is difficult to envision LxCxE interaction defects enhancing loss
of function of pRB-E2F binding defects through transcriptional control since the RB G
mutation already disrupts recruitment to E2F promoters 29,30. For this reason, we
investigated non-E2F dependent mechanisms that could be lost because of the RB L
mutation such as binding to CDH1. To investigate how E2F and CDH1 dependent arrest
mechanisms may relate to one another, we tested pRB’s ability to interact with each
simultaneously. For this experiment, we mixed C33A extracts containing myc-tagged
CDH1 with increasing amounts of HA-E2F3/DP1 extracts and tested their ability to bind
to GST-RBLP in pulldown experiments (Figure 3.3). This experiment reveals that
increasing quantities of HA-E2F3/DP1 prevent myc-CDH1 from binding to GST-RBLP
(Figure 3.3, left side). Disruption of E2F3 binding to pRB using a GST-RBLP G mutant
prevents competition with myc-CDH1 for binding to pRB. This experiment suggests that
pRB is unable to engage E2F3 and CDH1 dependent functions simultaneously,
suggesting that these functions are interchangeable. This mirrors findings from recent in
vivo approaches to pRB dependent cell cycle control 30, and this will be explored further
in the discussion.
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Figure 3.3: Competition between E2Fs and CDH1 for pRB binding.
Purified GST-RBLP or an -RBLPG mutant was incubated with constant levels of mycCDH1, and increasing quantities of HA-tagged E2F3/DP1 from transfected lysates.
GST-pulldowns were performed and associated levels of myc-CDH1 and HA-E2F3/DP1
were determined by western blotting. Western blots using anti-pRB antibodies show the
levels of GST-RBLP proteins precipitated in each experiment.
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3.4.2

A compound mutant mouse model demonstrates molecular
redundancy in RB control of DNA replication.
Mutation of all three binding surfaces in the RB large pocket was required to

maximally impair RB-mediated cell cycle control (Figure 3.2BE). This finding,
combined with the fact that individual mutations for each of these binding sites in gene
targeted mice did not phenocopy the Rb1-/- proliferative control defects in primary cell
culture, suggests that the function of pRB in cell cycle control may be composed of
several distinct mechanisms 28,29,32. To approximate the dysfunction of the RB GSL
mutation in vivo as diagrammed in Figure 3.1C, we combined our previously published
Rb1G/G animals that disrupts pRB-E2F interactions with p27 null mice (Cdkn1b-/-) to
eliminate its influence on cell cycle control 30. In addition, we crossed these mice into an
E2F1 null background to eliminate any effect on cell cycle regulation by the pRB-E2F1
specific interaction. This combination of mutations Rb1G/G; Cdkn1b-/-; E2f1-/-, represents
one potential scenario of the effects of the RB GSL mutation in vivo on cell cycle control.
Interestingly, Rb1G/G; Cdkn1b-/-; E2f1-/- (triple mutant) animals are viable and occur at
normal Mendelian ratios (Table 3.1).
Since triple mutant mice did not phenocopy the embryonic lethality seen in Rb1-/animals we next sought to determine if any tissues display loss of cell cycle control 41.
Previously, Mayhew et al. showed that tissue specific knockout of pRB in the murine
liver resulted in the up regulation of E2F target genes and ectopic DNA replication,
endoreduplication, and accumulation of nuclei with elevated ploidy 42. Since hepatocytes
often endoreduplicate it is possible to detect the accumulation of misregulated DNA
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Table 3.1: Frequency of compound mutant mice.

E2f1-/-; Rb1G /+; Cdkn1b+/X

E2f1-/-; Rb1G /+; Cdkn1b+/-

Genotype

P14

E2f1-/-; Rb1+/+; Cdkn1b+/+

8 (13)

E2f1-/-; Rb1+/+; Cdkn1b+/-

29 (26)

E2f1-/-; Rb1+/+; Cdkn1b-/-

12 (13)

E2f1-/-; Rb1G/+; Cdkn1b+/+

29 (26)

E2f1-/-; Rb1G/+; Cdkn1b+/-

64 (52)

E2f1-/-; Rb1G/+; Cdkn1b-/-

9* (26)

E2f1-/-; Rb1G/G; Cdkn1b+/+

12 (13)

E2f1-/-; Rb1G/G; Cdkn1b+/-

35 (26)

E2f1-/-; Rb1G/G; Cdkn1b-/-

10 (13)

Total

208

The indicated genotypes of mice were crossed and all resulting progeny were genotyped.
The number of live animals obtained at two weeks of age is indicated for each genotype
and the expected number based on Mendelian inheritance is indicated in brackets. *
Indicates significance as determined by chi-squared test.
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replication over time 35. We therefore, aimed to analyze aspects of cell cycle control in
the livers of Rb1G/G; Cdkn1b-/-; E2f1-/- animals to determine if these mutations were
capable of disrupting pRB control of DNA replication. H&E staining of livers revealed
that hepatocyte triple mutant adult livers had enlarged nuclei that on average were three
times larger that wild-type and Rb1G/G; Cdkn1b-/- double mutant animals as well as twice
as large as Rb1G/G and Rb1G/G; E2f1-/- nuclei (Figure 3.4AB). We also quantitated the
density of hepatocytes per microscopic field of view and did not see significant
differences between genotypes (Figure 3.4C). Since nuclear area in liver histology
correlates with DNA content 43, this suggested elevated levels of endoreduplication in
Rb1G/G; Cdkn1b-/-; E2f1-/- triple mutant livers. To test whether our triple mutant had
elevated ploidy in their hepatocytes, nuclei were extracted from livers of Rb1+/+, Rb1G/G,
and Rb1G/G; Cdkn1b-/-; E2f1-/- mice, stained with propidium iodine, and analyzed by flow
cytometry for DNA content. Consistent with previous results we found that Rb1+/+ livers
at 8 weeks of age display very low levels of 8N DNA content, however triple mutant
livers displayed a significant increase in the level of 8N DNA at this time point (Figure
3.4C), that is similar to what is reported when Rb1 is conditionally deleted in this organ
42

. This increase in nuclear size and subsequent DNA content indicates that triple mutant

livers undergo endoreduplication. While this is a normal phenotype for liver cells over
time, this suggests that the loss of these three regulatory elements controlled by pRB
results in earlier endoreduplication, potentially due to a loss of cell cycle control.
We next wanted to determine the effect of our combined mutations on the
regulation of pRB functions related to cell cycle control. To accomplish this, RNA was
isolated from adult livers to analyze the expression of E2F target gene transcription.
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Figure 3.4: Ectopic DNA-replication in Rb1G/G; Cdkn1b-/-; E2f1-/- compound mutant
mice.
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Figure 3.4: Ectopic DNA-replication in Rb1G/G; Cdkn1b-/-; E2f1-/- compound mutant
mice.
(A) H&E staining of liver sections from eight-week old wild type, Rb1G/G, double mutant
Rb1G/G; Cdkn1b-/-, and Rb1G/G; E2f1-/- mice, as well as Rb1G/G; Cdkn1b-/-; E2f1-/- triple
mutant animals. The scale bars represent 20 μm. (B) Nuclear size from the images in A
was determined and the mean size is indicated. Measurements were made from at least
50 nuclei, a, b, c represents statistically different groups as determined by ANOVA
followed by Tukey’s test (p<0.05). (C) Total number of hepatocytes per 20X field of
view was averaged from the indicated genotypes. No statistical differences were observed
by AVONA followed by Tukey’s test (p<0.05) (D) Nuclei were extracted from livers,
stained with propidium iodide, and analyzed for DNA content by flow cytometry. (E)
The relative expression level of six E2F cell cycle target genes from wild type, Rb1G/G,
and Rb1G/G; Cdkn1b-/-; E2f1-/- was determined from RNA extracted from 8-week-old
livers. (F) Eight-week-old mice were pulse labeled with BrdU two hours prior to sacrifice
and livers were sectioned and stained for BrdU. The percentage of BrdU positive nuclei
was determined. At least 500 nuclei were counted per mouse. All bar graphs represent at
least 3 individual experiments, and error bars indicate one standard deviation from the
mean. An asterisk represents a statistically significant difference from the wild type
control (t-test, P<0.05).
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Consistent with our previous findings, E2F target gene expression in Rb1G/G animals is
higher than wild-type levels 29. Interestingly, triple mutant livers show high expression of
some of these target genes (Figure 3.4E). However, in some cases, E2F target gene
expression is unchanged from wild type and this will be discussed later. To directly
measure proliferation in livers, 8-week-old animals were injected with BrdU to label
nuclei with actively replicating DNA. Livers were dissected, sectioned and stained for
BrdU incorporation. This analysis showed that while both Rb1G/G and Rb1G/G; Cdkn1b-/-;
E2f1-/- livers display increases in the expression of E2F target genes only triple mutant
livers displayed increased BrdU incorporation (Figure 3.4EF). Taken together with the
increased nuclear area and 8N DNA content in triple mutant livers, these results suggest
that by mutating the general binding site of pRB, and eliminating both p27 and E2F1, we
have recapitulated the DNA replication defects associated with conditional deletion of
Rb1 in adult livers. These in vivo results also mirror the effects seen in the SAOS2 arrest
assays that suggest that no individual protein interaction with pRB accounts for its
activity in cell cycle control. Instead, these data indicate that pRB likely sits in the center
of a network of regulators that control DNA replication and cell division.

3.5

Discussion

In this manuscript, we aimed to further the understanding of pRB-mediated cell
cycle control by disrupting pRB-binding interactions in the large pocket to quantitatively
account for its arrest mechanisms. This structure-function analysis demonstrated that to
disrupt the vast majority of pRB’s cell cycle arrest activity, three different binding
surfaces needed to be altered. Surprisingly, no single interaction site was indispensable
and disruption of some interaction sites had little effect on their own. We used a genetic
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cross to cripple these three aspects of pRB function endogenously and the combination
caused ectopic DNA replication in the liver. This suggests that pRB may interchangeably
use different protein interactions to influence cell cycle advancement. Insights and
caveats of our study are discussed below.
It is difficult to predict the proliferative control defects of an Rb1 deficient mouse
beyond neonatal lethality due to muscle atrophy 44. Interestingly, chimeric mice
composed of a mixture of wild type and Rb1-/- cells are viable and demonstrate normal
tissue cellularity, even in organs where Rb1-/- cells contribute extensively 17. This study
reveals that livers containing Rb1-/- hepatocytes display random, large nuclei, similar to
our findings in triple mutant livers 17. In addition, conditional ablation of Rb1 in the livers
of adult mice is reported to cause unscheduled DNA replication 42. The increase in DNA
copy number and BrdU incorporation was indicative of a loss of regulation of DNA
synthesis 42. In an effort to model the effects of the RBGSL mutant in vivo, we combined
Rb1G/G animals with p27 and E2F1 deficiency to produce triple mutant animals (Rb1G/G;
Cdkn1b-/-; E2f1-/-). This combination of mutations lead to a very similar DNA replication
phenotype in the liver as complete Rb1 deletion. While this is a similar phenotype as
conditional deletion of Rb1, by no means does our study elucidate all that pRB or E2Fs
do to block the cell cycle in this or other tissues. We anticipate that viability of triple
mutant mice suggests additional pRB dependent cell cycle arrest mechanisms likely
remain functional in these animals. Another important consideration in our efforts to
model the RBGSL mutant in vivo is that deleting Cdkn1b and E2f1 is not the equivalent to
disrupting the binding sites on pRB that regulate them, as these interaction sites may have
additional regulatory effects beyond the downstream targets we have chosen. In addition,
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loss of E2F1 could diminish cell proliferation even when entry into S-phase is
deregulated and this could further complicate the interpretation of our analysis of triple
mutant livers. Importantly, others have demonstrated that the choice between
proliferation and endoreduplication in hepatocytes is determined by opposing effects of
activator E2Fs (such as E2F1) and the E2F7 and E2F8 repressors 45,46. It is difficult to
predict how the triple mutant combination used here would affect the regulation of this
network of genes to cause a switch to endoreduplication. Future experiments using Rb1
gene targeted mice carrying a combination of G, S, or L mutations in a single allele will
help resolve some of these complexities.
We observed that some individual mutations contributed modestly to proliferative
control alone, and more strongly when in combination with other substitutions. We
suggest that this may be due in part to the competition between different cell cycle
control mechanisms for access to pRB. For example, we demonstrate that E2F3 and
CDH1 can compete for the opportunity to interact with pRB, and this is consistent with
previous reports of E2F1 and CDH1 competing for pRB 47. We suggest that CDH1
interactions with pRB are fundamentally different than other pRB interactors that contact
the LXCXE binding site simultaneously with E2Fs 3. Another way to consider
redundancy of function through endogenous pRB is a gene targeted mouse model bearing
an R654W mutation (the murine equivalent of the low penetrance human mutation
R661W). This mutation not only disrupts E2F binding, it also compromised interactions
at the LXCXE cleft 20, potentially illustrating the effects of multiple mutations in a single
pRB molecule akin to RBGC in our studies. Fibroblast cells from these mice possess many
features of deregulated proliferation seen in Rb1-/- cells and this mutation is lethal during
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embryogenesis 48. However, some aspects of pRB’s role in differentiation and its ability
to respond to senescence inducing stimuli and resistance to tumor formation are retained
48,49

, suggesting that simultaneous deficiency by pRB for multiple interactions can reveal

a more dramatic phenotype than loss of single interactions. This conclusion is further
supported by deregulated cell cycle control and cancer incidence in Rb1G/G; Cdkn1b-/mice50, suggesting loss of multiple pRB dependent proliferative control pathways can be
dramatically different than loss of a single pathway.
Consistent with multiple interactions needing to be compromised to abrogate cell
cycle arrest by pRB, we also note that some mutations tested in this study, such as the
M851A, V852A changes (RBS), have no effect on proliferative control in the SAOS2
assay on their own. We suggest that it may represent a latent proliferative control
mechanism used by pRB, and there may be others. A long standing puzzle in the RB field
has been the existence of proliferative control mechanisms that are mediated by the Nterminus of pRB, outside of the original growth suppressing large pocket domain 51-53.
Recent work has suggested that the N-terminus also plays a role in regulating DNA
replication 53. This may explain the phenotypic difference in proliferative control
between Rb1-/- animals and that of triple mutant Rb1G/G; Cdkn1b-/-; E2f1-/- animals as the
N-terminus is unaffected by our three mutations. There may also be redundancy between
N-terminal and large pocket growth arrest mechanisms. Provocatively, there are also low
penetrance mutations in human RB1 that target this region of pRB; further suggesting the
N-terminus contributes to pRB’s proliferative control and tumor suppressor functions 54.
We think that interchangeability of different pRB functions in proliferative control best
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explains our data and also encompasses additional work in the field that has previously
been difficult to reconcile.
RB dependent proliferative control is functionally inactivated in the vast majority
of cancers. This study furthers our understanding of the importance of the various
interaction surfaces of pRB and their roles in cell cycle control. In addition, CDK4/6
inhibitors have recently been developed to reactivate the RB-pathway in cancer 55-57.
Understanding the molecular interactions made by pRB and how they influence cell cycle
control and tumor suppression is crucial to the proper implementation of these drugs. We
expect that the mutational status of both pRB, as well as its regulation of p27 and E2Fs,
will play a critical role in the effectiveness of these drugs. We suggest that patients whose
tumor cells have pRB activatable p27 will benefit most from CDK4/6 inhibitors.

3.6
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Chapter 4

4

Tumor-suppressive functions of pRB independent of
E2F repression
4.1

Introduction

The maintenance of cell cycle control is crucial to the prevention of tumorigenesis 1.
Cell cycle progression is regulated through a number of checkpoints that ensure proper
signalling is present instructing the cell to grow and divide 1. Cancer develops when these
mechanisms are perturbed resulting in cells that continue to cycle regardless of the
presence or absence of growth stimuli1. To ensure that cells only replicate their genome
once per cell cycle the primary regulation of cellular division occurs prior to the onset of
DNA synthesis2. The transition from Gap 1 (G1) phase to that of synthesis (S) phase is
therefore also known as the restriction point2. Several intra- and extracellular signals
contribute to cell cycle decisions. These signals influence two main complexes which
control the restriction point and ultimately cell cycle entry, pRB and Cyclin E/CDK2 3,4.
These two proteins work in opposition to one another with pRB restricting cell cycle
entry and Cyclin E/CDK2 promoting division4.
Overall, cell cycle entry is determined by the total amount of Cyclin E/CDK2 activity
which is responsible for phosphorylating a vast network of transcription factors and is
critical in the firing of replication origins initiating the process of DNA replication 5. Both
Cyclin E/CDK2 and pRB can also influence the activity of each other ensuring that the
cell doesn’t undergo division prematurely or indecisively5,6. This interplay is primarily
due to the ability of Cyclin E/CDK2 to hyperphosphorylate pRB resulting in a
conformational change and subsequent release of the E2F transcription factors 4. The lack
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of pRB binding to E2Fs leads to the upregulation of the E2F transcriptional program
which contains several genes involved in S-phase progression, one of which is CCNE1
encoding Cyclin E6. This then increases the overall level of Cyclin E/CDK2 complexes
resulting in further phosphorylation of pRB4,5. This feed forward loop ensures that once
the cell is appropriately stimulated to divide the cell is committed to completing the cell
cycle5,7. In addition to regulating E2F-mediated transcription, we and others have
characterized an additional axis of pRB-mediated cell cycle control through the
stabilization of p278-10.
The two main functions which help to regulate cell cycle progression, E2F repression
and p27 stabilization are mediated through two independent binding surfaces 4,8. The first
and most well known is through the direct repression of E2F transcription factor activity,
facilitated through the pocket domain on pRB4. This interaction prevents the transcription
of genes required for DNA synthesis and cell cycle progression4. The second method of
pRB-mediated cell cycle control, p27 stabilization, is dependent on Cdh1 binding to pRB
through the LxCxE binding cleft (Chapter 3)9. This interaction enhances the ability of
APCCdh1 to degrade its target Skp2 resulting in the stabilization of p279,10. Stabilization of
p27 leads to the inhibition of Cyclin/CDK (Cyclin dependent kinase) complexes
preventing S-phase entry and DNA synthesis5
Given the importance of pRB in regulating both E2F target gene expression and CDK
activity, pRB plays a critical role in maintaining the G1 restriction point 4,9,10. As
disruption of the restriction point is a necessary step in carcinogenesis, it is unsurprising
that the pRB pathway is often the target of mutations in human cancers 11. Significantly,
the vast majority of mutations that disrupt pRB function are often upstream of pRB
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through the deletion of p16 or the amplification of Cyclin D leading to the
hyperphosphorylation of pRB11. The hyperphosphorylation of pRB simulates active
growth signalling resulting in E2F target gene expression and cell cycle entry.
However, recent studies have suggested that this is not the whole story10,12,13. In
particular, the Rb1G/G mouse model developed by Cecchini et al., in which pRb was
mutated to disrupt pRb-E2F binding, shows no overt phenotypes 12. This finding
demonstrates that the ability of pRB to repress E2Fs is dispensable for cell cycle control
and tumor-suppression12. In support of this hypothesis we have also shown that at least 3
different binding surfaces play a role in regulating cell cycle control (Chapter 3).
Two critical proteins which influence pRB and the cell cycle are Kras and p53 14,15.
These pathways are also typically mutated in human cancers 3,16. These two proteins work
in opposition to one another with Kras being activated through growth factor stimulation,
resulting in increased Cyclin/CDK activity and inactivation of pRB 14,15. By contrast p53,
which is stimulated by DNA damage, increases the transcription of the Cyclin dependent
kinase inhibitor p2115. The increased level of p21 inhibits the function of Cyclin/CDKs
thereby allowing pRB to remain hypophosphorylated and active, restricting cell cycle
progression15. The collective input from these signals along with others determines the
phosphorylation status of pRB, its subsequent activity, and overall cell cycle
progression4,14,15.
As we have previously shown, loss of E2F repression by pRB leads to tumorigenesis
in the absence of p27 (Chapter 2)8. To determine the importance of E2F repression by
pRB in tumorigenesis, we performed a series of genetic experiments where our Rb1G/G
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mice were combined with oncogenic KrasG12D as well as inactivation of the p53 pathway
through deletion of either p53 or p21. These crosses demonstrated that pRB-E2F
interactions are inconsequential in the face of constitutive proliferative signalling through
oncogenic Kras activation. However, regulation of E2Fs by pRB does influence tumorfree survival in conjugation with Trp53 deletion. Finally, we found that deletion of p21 in
the Rb1G/G background did not result in tumor formation despite having a defective DNA
damage response. This is of particular interest as an ineffective DNA damage response is
likely partially responsible for the pituitary tumor formation we observed in
Rb1G/G;Cdkn1b-/- animals in chapter 28.

4.2
4.2.1

Materials and Methods
Phenotypic analysis of animals.

LSL-KrasG12D mice (B6.129S4-Krastm4Tyj/J) mice and UBC-Cre-ERT2 (B6.CgTg(UBC-cre/ERT2)1Ejb/2J) were combined with our Rb1G/G mouse model to produce
both control KrasG12D; Cre-ERT2 animals and experimental Rb1G/G; KrasG12D; Cre-ERT2
animals12,17,18. Animals were then injected with 75mg/kg tamoxifen at 8 weeks of age
resulting in sporadic KrasG12D expression throughout the body. Animals were then
monitored for tumor formation and sacrificed at animal protocol endpoints. Survival data
were subjected to Kaplan-Meier analysis, and significant differences were compared
using a log rank test.
Trp53-/- mice (129-Trp53tm1Tyj/J), and Cdkn1a-/- mice (B6.129S6(Cg)Cdkn1atm1Led/J) have been described previously and were obtained from Jackson
Laboratory19,20. These two strains were combined with our previously described Rb1G/G
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mouse model and were genotyped as previously described12,19,20. Mice were monitored
for tumor development and sacrificed at animal protocol endpoints. Survival data were
subjected to Kaplan-Meier analysis, and significant differences were compared using a
log rank test. All animals were housed and handled as approved by the Canadian Council
on Animal Care.

4.2.2

Histological analysis of tumors
Following euthanasia, mice were subject to necropsy where tissues of interest

were fixed in formaldehyde for 72 hours. Tissues were then washed twice in PBS before
storage in 70% ethanol. Tissues were then embedded in paraffin, 5µm sections were cut
and stained with hematoxylin and eosin (H&E). Images were obtained using a Zeiss
Axioskop 40 microscope and Spot Flex camera and software (Mississauga, Ontario,
Canada).

4.2.3

Proliferation analysis
Mouse embryonic fibroblasts (MEFs) were derived from E13.5 embryos of the

indicated genotypes. Cells were cultured using standard methods in Dulbecco’s modified
Eagle’s medium containing 10% fetal bovine serum (FBS) 2mM glutamine, 50U/ml
penicillin and 50µg/ml streptomycin. Cells were treated with 15 Gy of ionizing radiation
as previously described8. 48 hours after treatment cells were labeled with BrdU for 2
hours. Cell cycle analysis was then carried out as previously discribed 21.

4.2.4

Expression analysis of pluripotency factors

MEFs of the indicated genotypes were cultured in Dulbecco’s modified Eagle’s
medium containing 10% fetal bovine serum (FBS) 2mM glutamine, 50U/ml penicillin
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and 50µg/ml streptomycin and RNA was isolated using Trizol reagent according to
manufactures instructions and previously published protocols 12. Expression levels of
Sox2, Klf4, Oct4, and Nanog were analyzed by qRT-PCR and normalized to GAPDH
using iQ Sybr-green Super mix (Bio-Rad) and the following primer sets: Sox2 Fwd
(5`ACAGATGCAACCGATGCACC 3`), Sox2 Rev (5`TGGAGTTGTACTGCAGGGCG
3`), Oct4 Fwd (5`ACATCGCCAATCAGCTTGG 3`), Oct4 Rev
(5`AGAACCATACTCGAACCACATCC 3`), Klf4 Fwd
(5`GCACACCTGCGAACTCACAC 3`), Klf4 Rev
(5`CCGTCCCAGTCACAGTGGTAA 3`), Nanog Fwd
(5`CCTCCAGCAGATGCAAGAACTC 3`), Nanog Rev
(5`CTTCAACCACTGGTTTTTCTGCC 3`). GAPDH Fwd (5`
GCACAGTCAAGGCCGAGAAT 3`), GAPDH Fwd. (5`
GCCTTCTCCATGGTGGTGAA 3`).

4.3
4.3.1

Results
Oncogenic KrasG12D-mediated development of squamous
papillomas is unaffected by loss of pRB-E2F interactions

Maintenance of the G1 to S-phase restriction point is critical at preventing aberrant
growth. The involvement of pRB in the G1 to S transition is well established however, as
demonstrated by Cecchini et al., and others pRB-E2F interactions are dispensable for cell
cycle arrest10,12,13. As derepression of E2F target genes in the Rb1G/G mice was unable to
lead to tumorigeneses we attempted to stimulate aberrant growth signalling in vivo by
combining the Rb1G mutation with oncogenic KrasG12D expression12,17. The KrasG12D
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Figure 4.1: Schematic representation of Ras signaling.
Following binding of growth stimulatory ligands receptor tyrosine kinases (RTKs). This
signals the activation of son of sevenless (SOS) and GRB2 which activate Ras. Following
activation, Raf is recruited to the membrane and phosphorylated by Ras. This signaling
cascade results in the activation of MEK1/2 and ERK1/2 by phosphorylation. Erk1/2 then
translocates to the nucleus and activates the transcription factor Myc/Max which results
in inhibition of transcription of cell cycle repressors such as p27. Additionally, Myc/Max
increases the expression of cell cycle promoting factors such as Cyclin D as well as E2F
target genes.
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mutation results in constitutive Kras signalling in the absence of normal growth
signalling17. Signalling through Kras results in a cascade that leads to an active Myc/Max
transcription factor which can regulate gene transcription driving the cell cycle (Figure
4.1). In particular, a decrease in the expression of Cdkn1b (p27) as well as an increase in
Cyclin D results in increased hyperphosphorylation of pRB and increased E2F activity3.
Additionally, the Myc/Max transcription factor can also induce the transcription of E2F
target genes further driving the cell into S-phase22. The inability of Rb1G to associate
with E2F suggests that in the face of increased E2F expression, the tumor-suppressive
ability of pRB would be compromised by this mutation. To induce expression of
oncogenic KrasG12D in adult tissues we used a Lox-Stop-Lox system which can activate
oncogenic KrasG12D expression following Cre recombinase activity17. This knock-in
strain was introduced into the Rb1G/G mouse line along with a transgene encoding Cre
recombinase fused to ERT2 hormonal response element 12,17,18.
Both control LSL-KrasG12D; Ert2-Cre+mice and experimental Rb1G/G; LSL-KrasG12D;
Ert2-Cre+ mice were produced at normal Mendelian ratios (Table 4.1). Typically, to
activate Ert2-Cre via tamoxifen injection, 75mg/kg is delivered intraperitoneally once per
day for a period of 5 days. However, following this protocol both control and
experimental mice reached endpoints within one week of the final injection without
tumor development. To induce more sporadic activation of KrasG12D expression and
thereby prevent the rapid decline of treated animals, we used an altered dosing regiment.
Eight-week-old Rb1G/G; LSL-KrasG12D; Ert2-Cre+ and LSL-KrasG12D; Ert2-Cre+ control
animals were injected with one dose of 75mg/kg tamoxifen. Tamoxifen then binds the
ERT2 element and shuttles Cre recombinase into the nucleus, removing the stop
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Table 4.1: Frequency of generation of Rb1G/G; KrasG12D; Ert2-Cre+ compound
mutant mice.
Rb1G/+; KrasG12D x
Rb1G/+; Ert2-Cre+
Observed Expected
Rb1+/+

12

8

Rb1+/+; KrasG12D

7

8

Rb1+/+; Ert2-Cre+

9

8

Rb1+/+; KrasG12D; Ert2-Cre+

9

8

Rb1G/+

15

17

Rb1G/+; KrasG12D

10

17

Rb1G/+; Ert2-Cre+

20

17

Rb1G/+; KrasG12D Ert2-Cre+

15

17

Rb1G/G;

18*

8

Rb1G/G; KrasG12D

6

8

Rb1G/G; Ert2-Cre+

6

8

Rb1G/G; KrasG12D Ert2-Cre+

8

8

Total

135

The indicated genotypes of mice were crossed and all resulting progeny were genotyped.
The number of live animals obtained at two weeks of age is indicated for each genotype
and the expected number based on Mendelian inheritance is indicated. * denotes
significance as determined by chi-squared test.
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cassette in front of the oncogenic KrasG12D allele allowing for expression (Figure 4.2A).
These mice were then monitored for tumor formation. Both Rb1G/G; LSL-KrasG12D; Ert2Cre and control LSL-KrasG12D; Ert2-Cre mice developed masses very early after
tamoxifen injection with an average survival of 56.5 days and 65 days post injection
respectively (Figure 4.2B). Necropsy also identified masses forming in the interior of the
mouth as well as on the stomach in both genotypes (Figure 4.2C). H&E staining of
sections of the masses removed from these animals identified them as squamous cell
papillomas (Figure 4.2C). Further, these masses appear to arise out of esophageal tissue
and have similar structures in both the mouth and stomach tumors (Figure 4.2C).
Importantly, the same tumor development as well as lifespan was seen both control
KrasG12D animals as well as experimental Rb1G/G KrasG12D cohorts (Figure 4.2BC).
Taken together this cross demonstrates that tumor development caused by oncogenic
KrasG12D expression is unaffected by the Rb1G mutation in the context of the squamous
papillomas which were produced. Conclusions about the interaction between oncogenic
Kras and the Rb1G mutations in other tumor types would require a tissue specific
approach.

4.3.2

Loss of E2F repression by pRB exacerbates the tumor
phenotype of Trp53-/- animals

In chapter 2 we have shown that the combination of Rb1G mutation and the deletion
of p27 lead to an ineffective DNA damage response and ultimately tumor formation 8.
This ineffective response to DNA damage seen in Rb1G/G; Cdkn1b-/- cells and animals
seems to suggest that Rb1G, which is incapable of inhibiting E2Fs, is still involved in the
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Figure 4.2: Expression of oncogenic KrasG12D leads to rapid tumor development
independent of E2F regulation.
(A) Schematic representation of tamoxifen induced expression of Kras G12D. Following
injection, tamoxifen binds to the ERT-Cre fusion protein leading to nuclear translocation.
Cre is then able to excise the stop cassette ahead of Kras G12D resulting in expression. (B)
Kaplan Meier analysis of tumor-free survival of indicated genotypes. Mice were
monitored until natural endpoint, those having tumors are shown. Rb1G/G; KrasG12D (56.5
days post injection) (n=6) and KrasG12D mice (65 days post injection) (n=4) are not
statistically different from one another using the log rank test (p=0.475). (C) Whole
mount and H&E analysis of squamous papillomas that develop in KrasG12D mice.
Squamous papillomas developed out of the mouth as well as stomach of both control
KrasG12D and Rb1G/G; KrasG12D animals. Scale bars are equal to 100µm.

115

DNA damage response8. To determine if insensitivity to DNA damage is the critical
factor resulting in tumor development in Rb1G/G; Cdkn1b-/- animals, Rb1G/G mice were
crossed into the Trp53-/- background which are known to have elevated levels of DNA
damage8,20. Under normal circumstances, following DNA damage ATM phosphorylates
and activates p5323. Active p53 then stimulates transcriptional programs leading to the
expression of genes that result in cell cycle arrest and apoptotic signalling23. Importantly,
p53 activation triggers the expression of Cdkn1a which encodes for p21 a CKI capable of
inhibiting the function of Cyclin/CDK complexes24. This in turn leads to the
hypophophorylation of pRB and subsequent cell cycle arrest (Figure 4.3).
Once again both Trp53-/-, and Rb1G/G; Trp53-/- mice were produced at appropriate
Mendelian frequencies (Table 4.2). The tumors inherent to the p53 knockout model
typically present as lymphomas and occasional sarcomas beginning around 6 months of
age for homozygous deletion (Figure 4.4B)20. The introduction of the Rb1G mutation into
the p53 null mouse line resulted in a decrease of both overall survival as well as tumor
free survival in the Rb1G/G; Trp53-/- animals (150 days) relative to Trp53-/- controls (194.5
days) (Figure 4.4AB).
Consistent with previous studies Trp53-/- animals presented with thymic lymphomas
(77%) and sarcomas (33%) (Figure 4.4C)20. Interestingly, while most of the Rb1G/G;
Trp53-/- animals developed thymic lymphomas (62.5%), 38.5% of animals spontaneously
died very young (average of 125 days) with no discernible tumor phenotype (Figure
4.4A). Whole mount and H&E stained sections of these tumors confirmed that those
masses that did develop in Rb1G/G; Trp53-/- animals were thymic lymphomas
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Figure 4.3: Schematic representation of p53 cell cycle arrest signaling.
Following genetic insults in the form of DNA damage, p53 is activated though ATMmediated phosphorylation. Following activation p53 can induce the transcription of a
variety of genes that are critical to the activation of apoptotic and cell cycle arrest
mechanisms. In particular, the expression of Cdkn1a, is primarily responsible for
initiating a p53 dependent cell cycle arrest. Following expression, p21 is then capable of
inhibiting Cyclin/CDK complexes which results in the hypophosphorylation of pRB and
subsequent cell cycle arrest.
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Table 4.2 Frequency of generation of Rb1G/G; Trp53-/- compound mutant mice.
Rb1G/+; Trp53+/- x
Rb1G/+; Trp53+/Observed Expected
Rb1+/+; Trp53+/+

33*

19

Rb1+/+; Trp53+/-

44

38

Rb1+/+; Trp53-/-

13

19

Rb1G/+; Trp53+/+

45

38

Rb1G/+; Trp53+/-

80

76

Rb1G/+; Trp53-/-

19*

38

Rb1G/G; Trp53+/+

20

19

Rb1G/G; Trp53+/-

39

38

Rb1G/G; Trp53-/-

12

19

Total

305

The indicated genotypes of mice were crossed and all resulting progeny were genotyped.
The number of live animals obtained at two weeks of age is indicated for each genotype
and the expected number based on Mendelian inheritance is indicated. * denotes
significance as determined by chi-squared test.
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Figure 4.4: Loss of E2F regulation by pRb exacerbates Trp53-/- tumor development.
(A) Kaplan Meier analysis of overall survival of indicated genotypes. Mice were
monitored until natural endpoint. Rb1G/G; Trp53-/- (140 days) (n=8), Trp53-/- (194.5 days)
(n=12) are statically significant from one another using the log-rank test (p<0.0001). (B)
Kaplan Meier analysis of tumor-free survival of indicated genotypes. Mice were
monitored until natural endpoint, those having tumors are shown. Rb1G/G; Trp53-/- (150
days) (n=5), Trp53-/- (194 days) (n=9) are statically significant from one another using
the log-rank test (p=0.0046). (C) Whole mount and H&E analysis of thymic lymphomas
found in both Rb1G/G; Trp53-/- and Trp53-/- mice. Scale bars are equal to 50µm.
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(Figure 4.4C). Given the propensity of double mutant Rb1G/G; Trp53-/- mice to
phenocopy Trp53-/- animals it suggests that the Rb1G mutation exacerbates the Trp53-/phenotype by removing an additional cell cycle checkpoint allowing for unchecked E2F
target gene expression.
The correlation between defective DNA damage signalling and tumor formation
in Rb1G/G; Cdkn1b-/- mice suggests that loss of appropriate DNA damage signaling in
Rb1G/G mice would result in pituitary tumor formation (Chapter 2)8. However, this was
not the case even though Trp53-/- MEFs display the same defective DNA damage
response found in Rb1G/G; Cdkn1b-/- MEFs25,26. One possible explanation for this finding,
is that due to the rapid morbidity of the p53 knockout mouse strain, it is difficult to
determine if the Rb1G mutation would lead to the development of pituitary tumors over a
longer period of time (Figure 4.4AB). Therefore, we wanted to determine the effect of
the Rb1G mutation in a mouse model which had the same cell cycle arrest problems in
response to DNA damage without rapid tumor development displayed by p53 knockout
stains. To address this question we chose to use the Cdkn1a-/- knockout model lacking
p21, which exhibits a defective cell cycle response to DNA damage without rapid
morbidity19.

4.3.3

Cdkn1a (p21) deletion is incapable of inducing
tumorigenesis in the Rb1G/G background

Following DNA damage, p53 activates a cell cycle arrest mechanism through the
transcriptional stimulation of Cdkn1a24. The Cdkn1a gene encodes for p21 which then
elicits a cell cycle arrest prior to DNA repair24. p21 is member of the CIP/KIP family of
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Cyclin dependent kinase inhibitors5. As such p21 can induce a cell cycle arrest through
the inhibition of a broad range of Cyclin/CDKs5. Importantly, previous publications have
shown that cells lacking p21 have a defective DNA damage response similar to that
exhibited in Rb1G/G; Cdkn1b-/- MEFs (Figure 4.5A)8,27. This included the inability to
arrest in response to ionizing radiation (Figure 4.5A) as well as rapid immortalization in
3T3 assays27,28. Despite these deficiencies tumor development in Cdkn1a-/- (p21 null)
mice is rare and inconsistent in the literature depending on strain background 27,29. Given
the rarity of cancers in Cdkn1a-/- mice and the lack of DNA damage response we chose to
combine p21 null mice with our Rb1G/G animals. By doing so we were able to determine
if the tumor development that we found in our Rb1G/G; Cdkn1b-/- double mutant mice was
dependent on a lack of an effective DNA damage response8. Additionally, this cross was
used to determine whether the tumor phenotype displayed in Rb1G/G; Cdkn1b-/- mice is
specific to p27 loss or if loss of p21 could result in the same effect 8.
Firstly, we confirmed the overall sensitivity of Cdkn1a-/- and Rb1G/G; Cdkn1a-/MEFs to DNA damage treatment (Figure 4.5A). As predicted by previous studies, p21
null MEFs display a defective arrest in response to ionizing radiation (IR) with or without
the inclusion of the Rb1G mutation (Figure 4.5A). Importantly, the defective arrest in
response to IR in p21 null and Rb1G/G; Cdkn1a-/- MEFs is similar to that of Rb1G/G;
Cdkn1b-/- MEFs (Figure 4.5A). Therefore, if the defective DNA damage response in
Rb1G/G; Cdkn1b-/- is responsible for tumor formation, Rb1G/G; Cdkn1a-/- would be
predicted to develop similar malignancies. Both Cdkn1a-/- and Rb1G/G; Cdkn1a-/- mice
were produced at appropriate Mendelian ratios (Table 4.3).
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Figure 4.5: Combination of the Rb1G mutation and loss of p21 (Cdkn1a-/-) does not
lead to tumor formation despite defective DNA damage response.
(A) Cell cycle analysis of MEFs following treatment with 15Gy of ionizing radiation. Sphase was determined by BrdU incorporation and Flow Cytometry. Average of 3
replicates are shown, error bars indicate standard deviation. * indicates p<0.05. (B)
Kaplan Meier analysis of overall survival of indicated genotypes. Mice were monitored
until natural endpoint. Rb1G/G; Cdkn1a-/- (419 days) (n=25), Cdkn1a-/- (442 days) (n=24)
are not statically significant from one another using the log-rank test (p=0.9059). (C)
Kaplan Meier analysis of tumor-free survival of indicated genotypes. Mice were
monitored until natural endpoint, those having tumors are shown as events. Rb1G/G;
Cdkn1a-/- and Trp53-/- are not statically significant from one another using the log-rank
test (p=0.7919). (D) H&E analysis of the two tumors found in Rb1G/G; Cdkn1a-/- and
Cdkn1a-/- mice. Scale bars are equal to 50µm. (E) whole mount images of pituitaries of
aged Cdkn1a-/- and Rb1G/G; Cdkn1a-/- animals demonstrate no hyperplasia. Pituitaries are
denoted by black arrows.
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Table 4.3: Frequency of generation of Rb1G/G; Cdkn1a-/- compound mutant mice.
Rb1G/+; Cdkn1a+/- x
Rb1G/+; Cdkn1a+/Observed Expected
Rb1+/+; Cdkn1a+/+

17

21

Rb1+/+; Cdkn1a+/-

64*

43

Rb1+/+; Cdkn1a-/-

26

21

Rb1G/+; Cdkn1a+/+

29*

43

Rb1G/+; Cdkn1a+/-

82

86

Rb1G/+; Cdkn1a-/-

39

43

Rb1G/G; Cdkn1a+/+

19

21

Rb1G/G; Cdkn1a+/-

37

43

Rb1G/G; Cdkn1a-/-

29

21

Total

342

The indicated genotypes of mice were crossed and all resulting progeny were genotyped.
The number of live animals obtained at two weeks of age is indicated for each genotype
and the expected number based on Mendelian inheritance is indicated. * denotes
significance as determined by chi-squared test.
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Surprisingly however, despite the homology between p21 and p27, Rb1G/G;
Cdkn1a-/- mice showed no change in overall survival as compared to Cdkn1a-/- controls
(Figure 4.5B). Furthermore, at endpoint the vast majority of these mice displayed no
observable masses (Figure 4.5C). Out of the 25 Rb1G/G; Cdkn1a-/- mice 1 had a mass in
the lower abdomen which has been identified as an angiosarcoma (Figure 4.3CD).
Additionally, one Cdkn1a-/- mouse had an oncocytoma which arose out of the kidney
(Figure 4.3CD). Importantly, these animals were far older, 334 and 485 days
respectively, than Rb1G/G; Cdkn1b-/- mice succumbing to pituitary tumors, which had an
average tumor free survival of 214 days (Chapter 2)8. Furthermore, the pituitaries of
these mice showed no overt aberrant growth, whereas tumor formation in Rb1G/G;
Cdkn1b-/- mice ubiquitously occurred in the intermediate lobe of the pituitary (Figure
4.5E)8.
Given the homology between p21 and p27 and the similar inability to respond
properly to DNA damage, it is surprising that p21 loss does not synergize with loss of
E2F repression as p27 does5,8. This suggests that p27 is playing a unique tumorsuppressive role which can not be compensated for by p21 (Figure 4.3A)28. As
mentioned in the introduction Rb1+/- animals develop normally into adulthood, however
following loss of heterozygosity, Rb1-/- cells result in pituitary tumor formation30,31.
Additionally Cre-mediated deletion of pRB in the pituitary of mice have resulted in the
same malignancy32. Several studies have attempted to modulate this phenotype through
the deletion of various genes (Table 4.4, 4.5). Co-deletion of p21, p27 or p53 in the
Rb1+/- background lead to a decreased tumor-free survival with the loss of additional
tumor suppressors (Table 4.4)33-35. By contrast co-deletion of Skp2 or E2f1 in the Rb1+/-
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Table 4.4: Effect of codeletion of various genes on pituitary tumor development in
Rb1+/- mice.
Gene

Survival of
Rb1+/-

Survival of
compound
mice

Change

Pathology

Citation

Id2-/-

276 days

334 days

+58 days

Pituitary tumors

36

Skp2-/-

~380 days

No
tumorigenesis

No
tumors

Pituitary tumors

37

Cdkn1b-/-

337 days

178 days

-159 days

Pituitary tumors

34

Cdkn1a-/-

340 days

261 days

-79 days

Pituitary tumors

33

Trp53-/-

357 days

105 days

-252 days

Lymphoma
(40%), Pituitary
(33%), Sarcoma
(14%), Other
(13%)

35

E2f1-/-

340 days

521 days

43

Pituitary tumors
(62%)

38

Table 4.5: Effect of codeletion of Sox2 on pituitary tumor development in
conditional Rb1-/- mice.
Control
Genotype

Experimental
Genotype

Survival of
mice

Phenotype
of control

Rb1f/f

Rb1f/f;
POMCCre

125 days

No tumors

Rb1f/f; Sox2f/f;
Rosa26CreER

Sacrificed
at 9 weeks
post
injection

Rb1f/f;
Rosa26CreER

(14 months)
Pituitary
tumors

Experimental Citation
Phenotype
Pituitary
tumors

32

No tumors

39
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background resulted in the rescue of pituitary tumorigeneses (Table 4.4)37,38. As both
E2F1 and Skp2 promote cell cycle entry and are both inhibited by pRB activity, the
deletion of these genes not surprisingly significantly reduced tumorigenesis (Table 4.4).
In addition to the deletion of these tumor-suppressors and oncogenes, two studies
have shown that the pituitary tumor phenotype is also rescued by the deletion of the
pluripotency factors Id2 and Sox2 (Table 4.4, 4.5)36,39. Sox2 is of particular interest as it
is a marker of pluripotency in the intermediate lobe of the pituitary40. This suggests that
the ability to maintain pluripotency is necessary to develop pituitary tumors in this
background39. These stem-like cells could be far easier to be transformed resulting in
tumor formation. Additionally, previous work has shown that both Rb1-/- cells and our
Rb1G/G cells reprogram into stem cells more efficiently than wildtype controls following
expression of reprogramming factors (Oct4, Klf4, cMyc, Sox2) 39. This raises the
possibility that E2F repression plays a role in maintaining a differentiated state.
Interestingly, while p21 and p27 play similar roles in their ability to regulate the cell
cycle through the inhibition of Cyclin/CDK complexes, Cdkn1b-/- cells show differential
reprogramming efficacy when compared to Cdkn1a-/- cells5,41. When only 2
reprogramming factors (Oct4, Klf4) were expressed in p21 and p27 null cells, p27 null
cells reprogrammed into stem cells at 4 times the rate of p21 null cells 41. Additionally,
the expression of the pluripotency factor Sox2, which is necessary for tumor development
in Rb1-/- pituitaries, is regulated by p2741. Chromatin immunoprecipitation has shown that
both pRB and p27 are capable of binding to the upstream enhancer SRR2 influencing
Sox2 expression39,41.
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To determine if there is an increased level of pluripotency factors inherent to the
Rb1G/G; Cdkn1b-/- MEFs we isolated RNA and performed qRT-PCR expression analysis
of 4 keys stem cell factors (Sox2, Oct4, Klf4, and Nanog). Overall, we found no
significant difference between the various genotypes tested, likely due to the huge
amount of variability present across samples (Figure 4.6). However, as stem cell factors
are expressed at very low levels in non-stem cells it is not surprising from one population
to the next the expression of these factors may vary wildly. In summary, the lack of a
tumor phenotype in Rb1G/G; Cdkn1a-/- animals lacking 21 as compared to the pituitary
tumors formed in Rb1G/G; Cdkn1b-/- mice missing p27, suggests that p27 is playing a
unique tumor suppressive role in addition to cell cycle arrest mechanisms following DNA
damage in the context of the Rb1G mutation (Figure 4.5BC)8. This role may include
prevention of stem cell like reprogramming, however more studies are required to fully
address these questions.

4.4

Discussion

In this chapter, we aimed to investigate the tumor-suppressive abilities of pRB
independent of E2F transcription factor repression. We show that, while the Rb1G
mutation does exacerbate the tumor development of Trp53-/- mice, there is no effect on
tumor-free survival in the presence of oncogenic KrasG12D expression, nor following loss
of p21 (Cdkn1a-/-). In conjugation with the results presented in chapter 2 demonstrating
that Rb1G/G; Cdkn1b-/- animals, lacking p27, form pituitary tumors, these genetic crosses
provide an interesting picture of how pRB-E2F interactions influence tumor-suppression
in the face of various cancer causing mutations8.

127

Figure 4.6: Expression of pluripotency factors Sox2, Klf4, Oct4, and Nanog, in
Rb1G/G; Cdkn1b-/- MEFs.
Expression of genes was determined by qRT-PCR, normalized to GAPDH. Average of 3
replicates is shown, error bars indicate standard error. No statistically significant
differences were found among any genotypes as determined by one-way ANOVA and
Tukey’s test (p>0.05).
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The expression of the Rb1G mutation in the presence of oncogenic Kras G12D had no
effect on tumor free survival (Figure 4.2B). One compelling explanation for this finding
is uncovered through analysis of the method by which oncogenic Kras leads to tumor
formation. Overall, oncogenic Kras G12D causes a signalling cascade which results in both
the expression of E2Fs, an increase in Cyclin/CDK complexes and the suppression of p27
activity14,15. Importantly, although KrasG12D activation results in increased activity of
E2Fs, which can not be sequestered by pRBG, the increased Cyclin/CDK activity results
in the hyperphosphorylation of pRB3. This in turn leads to the compaction of the pRB
protein and the complete disruption of both the pRB pocket domain and the LxCxE
binding cleft which eliminates the E2F regulatory and p27 stabilization functions of pRBmediated cell cycle control respectively4. As such, the expression of oncogenic KrasG12D
results in the hyperphophorylation of pRB and any effect that pRB G could have been
masked by the complete disruption of pRB-mediated cell cycle control. Alternatively, the
extremely fast rate at which expression of KrasG12D induces tumor development it is
possible that the Rb1G mutation could not cooperate to achieve any change in tumor
latency. Potentially future studies using tissue specific Cre driver lines may cause slower
growing tumors and the Rb1G mutation may alter the kinetics.
Our findings in chapter 2 demonstrated that the combined loss of pRB-E2F repression
and p27 results in a defective DNA damage response and eventual pituitary tumor
formation (Chapter 2)8. Furthermore, this defective arrest was also seen in embryonic
pituitaries of combined mutant mice (Rb1G/G; Cdkn1b-/-)8. As these findings suggest a
defective DNA damage response is involved in the tumorigenesis observed, we aimed to
better understand the involvement of pRB-E2F interaction in this paradigm. By
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introducing our Rb1G mutation into the Trp53-/- background we determined the tumorsuppressive capabilities of Rb1G in the presence of elevated DNA damage inherent to
Trp53-/- mice20. The fact that Rb1G/G; Trp53-/- mice develop similar tumors with faster
kinetics to that of Trp53-/- controls indicates that pRB-E2F interactions are important for
regulating cellular responses to DNA damage, but not the tumor tropism (Figure
4.4AB)20.
Interestingly, this function must lie outside of canonical understanding of pRB
activation following DNA damage. Under wild-type conditions, DNA damage would be
identified and ATM/ATR kinases would stabilize and activate p53 through
phosphorylation15. This in turn would upregulate a number of genes, one of which is p21
encoded by the CDKN1A gene15. Once expressed, p21 is then able to bind to and inhibit
the activity of Cyclin/CDK complexes maintaining pRB in a hypophosphorylated state 4,5.
The fact that Rb1G/G; Trp53-/- show decreased tumor-free survival as compared to
controls suggests that pRB is still playing a role in tumor-suppression in the presence of
DNA damage despite the inability of signaling to propagate via p53 and p21 to pRB 24.
One possible explanation for this is that, Rb1G/G; Trp53-/- mice have reduced survival
simply due to cells harboring an additional mutation in a critical binding pocket of an
important tumor suppressor, the general E2F interacting site. This line of thinking would
indicate that the pRB and p53 pathways in this context are functioning independently and
the loss of p53 as well as E2F transcriptional repression simply makes a cell more
amenable to tumorigenesis.
Lastly, to test the effect of the Rb1G mutation in a mouse model harboring a defective
DNA damage response, we combined our Rb1G/G mutant mouse with the Cdkn1a-/-
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background which have a deletion of p21. Given the high degree of homology between
p21 and p27 it is surprising that Rb1G/G; Cdkn1a-/- mice do not show any tumor incidence
in contrast to Rb1G/G; Cdkn1b-/- animals, which ubiquitously develop pituitary tumors
(Figure 4.5BC)8. p21 and p27 are both members of the CIP/KIP family of CKIs which
influence cell cycle control through the inhibition of Cyclin/CDK activity5. When
combined with the Rb1G mutation, p27 deletion prevents cells from responding
appropriately to DNA damage, potentially leading to the development of the pituitary
tumors observed8. Importantly, the defective cell cycle arrest in response to DNA damage
exhibited in the Rb1G/G; Cdkn1b-/- cells is also present in cells null for p21 (Figure
4.5A)27,28. Together this indicates that p27 must be playing a specific role in preventing
tumor formation when pRB-E2F interactions are disrupted that can’t be compensated for
by p21, and is therefore is beyond influencing DNA damage induced cellular arrest.
One role of p27 that is unique among CIP/KIP family members is the ability to
regulate the expression of the Sox2 gene through the regulation of the SRR2 enhancer41.
Sox2 is a pluripotency factor that is critical to the development of the pituitary40.
Additionally, Sox2 is required to allow for tumor formation in Rb1-/- pituitaries39. This
expression of a pluripotency factor could lead to a more stem-like phenotype in Rb1G/G;
Cdkn1b-/- pituitaries resulting in transformation and subsequent tumor formation.
However, when analyzed by qRT-PCR we found no differences in the overall level of
these factors in any of the genotype tested (Figure 4.6). Importantly, in this experiment
we found a huge degree of variability in the expression of these genes likely due to their
overall low abundance in non-stem cells. Additionally, stem-cell reprogramming occurs
at a cell to cell basis. Even when cells are reprogrammed through the expression of the
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canonical reprogramming factors (Oct4, Klf4, cMyc and Sox2) this is a rare event 39.
Therefore, the lack of any meaningful change in the expression of the stem cell markers
(Sox2, Klf4, Oct4 and Nanog) in MEF population is perhaps unsurprising as any
alteration can be drowned out by population effects (Figure 4.6). While we have not
discerned a direct link between our Rb1G/G; Cdkn1b-/- MEFs and increased amenability to
stem cell reprogramming this remains a formal possibility which requires further
investigation.
Overall, we show that our Rb1G mutation can enhance the ability of cells to form
tumors in Trp53-/- mice (Figure 4.4B). However, in the presence of the oncogenic driver
mutation KrasG12D, the inability of pRB to regulate E2F target transcription did not affect
tumor-free survival (Figure 4.2B). Finally, the surprising finding that p21 and p27
deletion have very different phenotypic effects in our Rb1G/G mutant animals indicates
that p27 has a unique tumor-suppressive role in the absence of pRB-E2F interactions
(Figure 4.5C)8.
The findings of these genetic crosses may have important implications in the practical
use of a novel family of cancer therapeutics, CDK4/6 inhibitors by providing diagnostic
markers for effective treatment administration. Specifically, re-activation of pRBmediated cell cycle control would be most effective in tumors which retain p53 activity
and would likely not be effected p21 deletion. Finally, as oncogenic Kras G12D typically
influences tumorigenesis through the hyperphosphorylation of pRB, use of CDK4/6
inhibitors in these tumors would likely be an effective strategy to combat tumor growth.
Provided, of course, that adequate inhibition of CDK4/6 can be achieved in the presence
of oncogenic Kras. Further studies analyzing CDK4/6 inhibitors in cells harboring these
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mutations will provide additional information towards more effective administration of
these novel compounds.
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Chapter 5

5

Discussion
5.1

Summary of findings

The retinoblastoma tumor-suppressor protein (pRB) has been the subject of a
significant volume of research that aims to understand the mechanism through which
pRB can prevent tumorigenesis. Originally predicted through the genetic analysis of
children developing retinoblastoma, pRB is now often described as the main gate-keeper
of the G1 to S-phase transition of the cell cycle and whose activity is perturbed in a
majority of human tumors1-3. pRB-mediated cell cycle control is maintained through the
repression of the E2F family of transcription factors which influence the transcription of
genes required for S-phase entry4,5. However, the function of pRB resists simplicity as a
growing body of literature has been suggesting new roles in cell cycle control and tumor
suppression independent of E2F transcriptional repression 6-10. Building on this, Cecchini
et al., through the development of the Rb1G/G mouse model, demonstrated that the loss of
pRB-E2F interactions is largely dispensable for cell cycle control and tumorsuppression11. In this thesis, by exploiting the Rb1G/G mouse model, I continued to
explore the tumor-suppressive ability of pRB outside of pRB-E2F interactions, using a
variety of in vitro and in vivo approaches to further characterize these interactions.
My findings in this thesis demonstrate that cell cycle control and tumorsuppression by pRB is multifaceted and extends beyond simple repression of E2F
transcription factors. In chapter 2, through analysis of the Rb1G/G mouse model in
combination with loss of p27 we present in vivo evidence of an E2F independent

137

mechanism of pRB-mediated cell cycle control through the stabilization of p27 in
response to DNA damage12. As pRB-E2F interactions are dispensable for this function, in
chapter 3, we next explored the various contributions to cell cycle control of 3 specific
binding surfaces in the pRB large pocket. These experiments confirmed that the RB
pocket domain, LxCxE binding cleft, and the E2F1 specific site all contribute to cell
cycle control as determined by Saos-2 cell cycle arrest assays as well as in vivo analysis
of murine livers. Finally, through a series of genetic experiments we were able garner
further information about pRB-mediated tumor-suppression outside of E2F target gene
repression (Chapter 4). Together the experiments presented in this thesis outline the
importance of the entire pRB large pocket, the regulation of cell cycle, and tumor
suppression. These findings are consistent with the prevalence of cancer derived
mutations that result in the complete inactivation of pRB typically through
hyperphosphorylation3.

5.2
Evidence for pRB as a multifaceted regulator of
cell cycle control
The work presented in this thesis highlights and addresses the disparity between the
linear model of pRB-mediated tumor suppression (Figure 5.1A) and a growing body of
literature which points towards pRB-mediated tumor suppression as a function of the
regulation of multiple pathways controlled through the various pRB interacting domains,
the network model (Figure 5.1B). This idea that pRB-mediated tumor-suppression is
dependent on several interactors, provides compelling explanations for several unusual
findings which would be odd in the context of the linear model of cell cycle control by
pRB through E2F repression. Firstly, even though the pRB large pocket
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Figure 5.1: pRB utilizes multiple mechanisms to ensure cell cycle control and
tumor-suppression.
Human tumors often contain deletion mutants of p16 or amplifications of Cyclin D
resulting in the hyperphosphorylation of pRB. (A) Linear model of pRB-mediated tumor
suppression. Following inactivation of pRB by phosphorylation, E2F is released and is
responsible for driving cell entry leading to tumorigenesis. (B) Network model of pRBmediated tumor suppression. pRB sits at the center of a network controlling at least three
methods of cell cycle control and tumor suppression: E2F repression, p27 stabilization
and regulation of E2F1 via the pRB-E2F1 specific interaction.
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is the minimal domain necessary both for E2F interactions and to initiate a cell cycle
arrest in Soas-2 cells, this region also contains the LxCxE and specific site binding
surfaces (Figure 1.2B)13,14. Importantly however, later studies exploiting pRB variants
which specifically disrupt pRB-E2F interactions demonstrated that pRB could still retain
some level of cell cycle control despite the inability of pRB to regulate E2F target gene
expression10,15. Additionally, investigation of viral oncoproteins capable of inactivation
of pRB, in particular E1A, required the elimination of both pRB-E2F interactions as well
as LxCxE interactors through the stable binding of E1A’s CR1 and CR2 domains to
pRB16. This notion that the ability of pRB to regulate the cell cycle is mediated both by
the pocket domain and the LxCxE binding cleft is further evidenced by the
conformational changes that occur to pRB following hyperphosphorylation 6.
Hyperphosphorylation results in the compaction of the pRB protein and the blocking of
both the pRB pocket domain as well as the LxCxE binding cleft 6. Taken together these
findings provide a solid foundation which suggests that the role of pRB in regulating the
cell cycle extends well beyond the repression of E2F transcription factors. Finally, our
lab has produced three strains of mice which target the three binding surfaces discussed
in this thesis: the pocket domain (Rb1G/G), the LxCxE binding cleft (Rb1L/L) and the pRBE2F1 specific interaction (Rb1S/S)8,11,17. These animals are viable and develop normally,
which is in direct contrast to Rb1-/- mice which are embryonic lethal further supporting
the notion that pRB regulates cell cycle control and tumor suppression through a
multifaceted approach11,18.
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5.3
Prevalence of perturbations to pRB function in
cancer
Given that pRB acts as a critical gate-keeper to cellular division it is perhaps
unsurprising that the pRB pathway is perturbed in a large majority of human cancers 3.
Interestingly however, mutations in pRB itself is relatively rare outside of small cell lung
cancer, retinoblastoma and osteosarcoma (Figure 5.2A)3. Typically, mutations in the
pRB pathway occur upstream of pRB (Figure 5.2B)3. These mutations typically include
amplifications of Cyclins, or their catalytic partner CDK, as well as deletions of Cyclin
dependent kinase inhibitors (CKIs) (Figure 5.2B). The functional consequence of these
alterations would be the hyperphosphorylation of pRB and subsequent loss of binding to
both the pRB pocket domain and the LxCxE binding cleft 3,6. Furthermore, the majority of
those mutations that do occur within the coding sequence of pRB typically result in the
formation of novel stop codons (Figure 5.2C). This in turn creates a non-functional
truncated protein. Finally, the small subset of mutations in the pRB coding sequence that
do result in missense changes are equally spread across the coding region (Figure 5.2D).
Using a binomial distribution test with a Bonferroni correction we determined if any of
the missense changes occurred at a frequency higher than expected (Figure 5.2D). While
some amino acid changes did appear more often than expected, all of them are buried in
the interior of the pocket domain of pRB based on previous analysis and are not likely to
influence interactions19. However, these changes substitute small amino acids for large
ones, which could significantly disrupt the overall structure of pRB leading to a
dysfunctional protein.
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Figure 5.2: Direct pRB mutation is relatively rare in human cancers and mutations
that do exist result in null alleles.
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Figure 5.2: Direct pRB mutation is relatively rare in human cancers and mutations
that do exist result in null alleles.
(A) Incidence of RB1mutation, deletion or amplification in the ten most common human
malignancies. Data obtained from C-bio portal (2017). (B) Incidence of p14, p15, p16,
p18, p21, p27, CyclinA1-2, B, D1-3, E1-2, CDK1/2/4/6 mutation, deletion or
amplification in the ten most common human malignancies. Data obtained from C-bio
portal (2017). (C) Breakdown of coding sequence mutations in RB1 and TP53 Data
obtained from C-bio portal (2017). (D) Alignment of cancer derived mutations occurring
in the RB1 coding region, as curated by C-bio portal (2017). (E) Alignment of cancer
derived mutation occurring in the TP53 coding region, as curated by C-bio portal (2017).
Dashed lines indicate threshold for significance of p<0.001 of mutational frequency
(RB1=4 and TP53=27) as determined by binomial distribution with a Bonferroni
correction.
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The lack of hotspot mutations in critical interaction domains of RB1 is peculiar given
the importance prescribed to pRB-E2F interactions in pRB-mediated tumor suppression.
By comparison, other tumor suppressors such as TP53 and PTEN are dominated by
missense mutations that disrupt well defined hotspots which occur within critical
structures of the protein such as the DNA binding domain of p53 and the phosphatase
domain of PTEN (Figure 5.2E)20,21. The fact that pRB is inactivated in the majority of
human cancers through hyperphosphorylation or nonsense substitutions suggests that
pRB is a crucial tumor-suppressor that must be overcome to allow for cancer
development and progression3. Secondly, the lack of missense mutations in the RB1 gene
demonstrates that the tumor suppressive function of pRB is likely not limited to a single
interaction as is the case for p53 through its DNA binding domain (Figure 5.2C-E)21.
Instead these findings imply that multiple functions of pRB contribute to its tumorsuppressive functions and as such, disruption of the whole protein through deletion,
truncation, or hyperphosphorylation is more prevalent in human tumors (Figure 5.2BD)3. Moreover, this hypothesis is supported by our data which suggested that at least 3
different binding surfaces contribute to the cell cycle control as mediated by pRB
(Chapter 3). Finally, the requirement for additional tumor-suppressive pathway
disruptions in the Rb1G/G background is consistent with the complete disruption of pRB
function through hyperphosphorylation or truncation seen in human tumors. (Figure
5.2B-D) (Chapter 2, 4)11,12.

5.4

Non-canonical functions of p27

One of the most striking findings presented in this thesis is the stark phenotypic
difference between Rb1G/G; Cdkn1a-/- mice, lacking p21 and Rb1G/G; Cdkn1b-/- mice
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which have a deletion of p27. As discussed in the results chapters, Rb1G/G; Cdkn1a-/mice, deficient for p21, showed relatively limited overt phenotypes, with the
development of only 1 malignancy out of 25 animals (Figure 4.5C). Importantly there
was no difference in terms of overall or tumor free survival when compared to Cdkn1a-/controls (Chapter 4). By comparison, Rb1G/G; Cdkn1b-/- mice, lacking p27, ubiquitously
developed pituitary tumors with a tumor free survival of 214 days, while control Rb1G/G
and Cdkn1b-/- animals showed no tumor development (Chapter 2)12. Taken together,
these results indicate that p27 is playing a unique role in regulating pRB-mediated tumor
suppression. This is surprising considering there is a high degree of homology between
p21 and p27 and the fact that both contribute to the regulation of the cell cycle through
the inhibition of a broad range of CDKs22. As deletion of p21 in the Rb1G/G background
did not result in tumor formation we can conclude that p27 is influencing pRB in a
manner that is independent of cell cycle control in the presence of DNA damage as this is
also defective in Cdkn1a-/- and Rb1G/G; Cdkn1a-/- MEFs lacking p21.
In addition to the ability of p27 to influence the cell cycle, through the inhibition of
CDKs, non-canonical roles in tumor suppression for p27 have been described 23.
Interestingly, some of these alternative functions of p27 are tumor-suppressive whereas
others are oncogenic23. As discussed in chapter 4, p27 has been implicated in the
maintenance of stemness of cells, a characteristic of tumor cells, and in particular cancer
stem cells (CSCs) which can give rise to metastasis 23,24. Overall p27 levels are relatively
low in undifferentiated cells and differentiation coincides with an increase in p27 25,26.
Moreover, p27 has been shown to be a transcriptional repressor of SOX2 in different cell
lines27. Furthermore, Cdkn1b-/- animals lacking p27, display increased expression of Sox2
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in a variety of tissues27. Finally, Li et al. also demonstrated that the gigantism phenotype
displayed in some strains of Cdkn1b-/- animals can be rescued with the co-deletion of
Sox2, implying that Sox2 overexpression in the absence of p27 can result in aberrant
growth27. This result together with the finding that both Rb1G/G and Cdkn1b-/- MEFs
reprogram more efficiently than wildtype controls, suggests a potential mechanism of
tumorigenesis in Rb1G/G; Cdkn1b-/- animals27,28. The role for p27 in transcriptional
repression also extends beyond the regulation of Sox2, through the formation of
transcriptional repressor complexes with p130 and E2F4 29. This complex is then capable
of recruiting co-repressors such as HDACs which can compact the DNA around various
target genes including those involved in RNA processing and the cell cycle 29. Importantly
while this repression is lost following p27 deletion, a mutant version of p27, which is
incapable of inhibiting CDKs (p27CK) is as efficient as wildtype in repressing
transcription29.
Critical to the function of p27 is its subcellular localization, cytoplasmic or nuclear.
While the ability of p27 to inhibit Cyclin/CDKs and transcriptionally repress genes
involved in cell cycle, RNA processing and pluripotency occurs in the nucleus, additional
roles for p27 in the cytoplasm have also been described30,31. Following phosphorylation
of p27 on S10, p27 is exported from the nucleus 32. However, the ramifications of
cytoplasmic p27 are unclear as p27 appears to have both tumor-suppressive and
oncogenic functions23,30,32,33. Cytoplasmic p27 can inhibit cell cycle progression through
the disruption of the Ras signalling cascade30. Through interaction with GRB2, p27 can
attenuate Ras signalling by disrupting GRB2-SOS interactions 30. This in turn prevents the
activation of the Ras signalling cascade30. Consistent with this finding, in the absence of
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p27, Ras signalling remains activated at a higher level than controls resulting in Erk1/2
phosphorylation, MAPK target gene expression, and faster cell cycle entry33.

5.5
Cytoplasmic p27 regulates cellular migration and
invasion
In opposition to the tumor suppressive functions described above, cytoplasmic p27
has also been shown to be tumorigenic through the regulation of actomyosin 31. Indeed,
cytoplasmic p27 is a marker of poor prognosis in melanoma34. Additionally, mouse
models harboring a mutation disrupting the S10 site required for cytoplasmic localization
of p27 (p27S10A), are resistant to tumor development in response to urethane treatment 32.
Following cytoplasmic localization, p27 associates with RhoA, inhibiting RhoA from
becoming activated by GTP31. This inhibition of the RhoA-ROCK pathway results in the
loss of actomyosin stability and leads to increased migration and invasion 31. However,
this promotion of migration by p27 is not universal and in several cell types p27 has been
shown to inhibit migration35-38.
Overall, several non-canonical functions of p27 have been described, which may help
to understand why Rb1G/G; Cdkn1b-/- animals developed pituitary tumors where as
Rb1G/G; Cdkn1a-/- animals, deficient for p21, generally showed no tumor phenotype
(Chapter 2,4)12. It is possible that the loss of p27 results in a combination of factors
which maintain a stem cell like state and promote proliferation through the upregulation
of cell cycle target genes and increased Ras signalling, however further studies are
necessary to fully elucidate this mechanism27,29,30.
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5.6

Perspectives and therapeutic implications

The work presented in the thesis has enhanced our understanding of pRB-mediated
cell cycle control and tumor-suppression. Using a variety of techniques, we have shown
that the linear model of pRB repression of E2F target genes is incomplete (Figure 5.1A).
Instead, pRB sits in the center of a network of regulation activating multiple downstream
pathways which together maintain cell cycle control and prevent tumorigenesis (Figure
5.1B). This multifaceted approach to cell cycle regulation by pRB provides a number of
redundant mechanisms, through which the cell can prevent tumorigenesis. This finding is
also supported by the relative rarity of missense mutation in the Rb1 coding sequence
(Figure 5.2D). Instead, cancers typically harbor mutations in upstream pathway
members, which result in the hyperphosphorylation of pRB and subsequent functional
inactivation (Figure 5.2AB). This method of pRB inactivation through phosphorylation
allows the possibility of therapeutic intervention through the inhibition of the upstream
kinases responsible for pRB phosphorylation.
Currently there are three drugs which aim to restore pRB activity through the
inhibition of pRB phosphorylation in cancer cells: Palbociclib (Pfizer), Ribociclib
(Novartis) and Abemaciclib (Eli Lilly). These compounds work by inhibiting upstream
kinases of pRB, CDK4 and CDK6. Following inhibition of CDK4/6, pRB becomes
hypophosphorylated and can re-activate its various cell cycle functions including those
highlighted in this thesis. Currently, Palbociclib is approved for use in ER+ breast
cancers in combination with letrozole. In addition, Ribociclib and Abemaciclib are in
phase three clinical trials. To insure effectiveness of treatment by these drugs, only
patients with wildtype pRB are given these inhibitors. However, pRB-mediated cell cycle
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control and tumor-suppression is a product of a network of pathways which may
influence the effectiveness of these inhibitors. Through our various genetic crosses in the
absence of pRB-E2F interactions we have shown that loss of p27 or p53 result in
enhanced tumorigenesis. Therefore, we would predict that the presence of both wildtype
p27 and p53 would likely enhance the effectiveness of these CDK4/6 inhibitors in
patients. Importantly, in addition to disrupting DNA damage response signalling, p27
appears to play a unique, non-CKI role in regulating tumor-suppression in the absence of
pRB-E2F interactions12. While this function is currently unknown, several non-canonical
functions of p27 have been previously identified and largely depend on the subcellular
localization of p2723. Therefore, in addition to the expression level and mutational profile
of p27, subcellular localization may be a critical determinant for the effectiveness of this
new class of CDK4/6 inhibitors.
In the several years following the discovery of pRB, the field has been dominated by
the linear model through which pRB is tumor-suppressive by way of regulating E2F
transcription factors (Figure 5.1A). However, in recent years, several non-canonical
functions of pRB have been described. Through the development and use of the Rb1G/G
mouse model we had the unique opportunity to look at these pRB-mediated, non-E2F
methods of cell cycle control in vivo11. Moreover, as the Rb1G/G animals avoid the
embryonic lethality of Rb1-/- mice, using this model we can specifically study pRB
functions in tumorigenesis as opposed to development. The fact that pRB-E2F
interactions are dispensable for cell cycle control and tumorigenesis, indicates that other
pathways must play significant roles in regulating cell cycle control and tumorsuppression11. Through a variety of in vitro, cell culture and in vivo approaches we have
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identified at least three interacting domains in the large pocket of pRB which play a role
in modulating cell cycle control (Chapter 3). Furthermore, the loss of pRB-E2F
regulation interacted synergistically with Cdkn1b deletion resulting in an ineffective
DNA damage response and eventual tumor formation (Chapter 2)12. Finally, the Rb1G
mutation dramatically shortened the lifespan of p53 null animals while not effecting the
outcome of mice expressing oncogenic KrasG12D nor those lacking p21 (Chapter 4).
Critically, the lack of phenotype of Rb1G/G; Cdkn1a-/- mice lacking p21 as compared to
Rb1G/G; Cdkn1b-/- lacking p27, suggests that p27, is playing a unique role in modulating
the tumor-suppressive function of pRB. However, the inhibition of CDKs in response to
DNA damage cannot be ruled out as a contributing factor to the tumor development in
Rb1G/G; Cdkn1b-/- animals. To definitively determine if the tumorigenesis observed in
Rb1G/G lacking p27 is dependent on the ability of p27 to inhibit CDKs, Rb1G/G mice
would have to be combined with the p27CK mutation. Overall this thesis presents several
lines of evidence which suggest that pRB is a hub protein at the center of a network of
functions which together result in cell cycle control and tumor-suppression.
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Appendix B: List of plasmids
Name

Genes
Encoded

Mutations

Obtained/
Stock
Constructed Resistance Number

pScodonGST-RBLP

GST,
RBLP

N/A

F. Dick

AMP

0519

pMJC15

GST,
RBLP

Y756W

M. Cecchini

AMP

0661

pMJC02

GST,
RBLP

R467E, K548E

M. Cecchini

AMP

0561

pscodonGST-RB delta
L

GST,
RBLP

I753A, N757A,
M761A

S. Talluri

AMP

0668

pscodon1GST-RBdS

GST,
RBLP

M851A, V852A

O. Palander

AMP

0528

pMJC17

GST,
RBLP

R467E, K548E,
Y756W

M. Cecchini

AMP

0613

pMJC09

GST,
RBLP

R467E, K548E,
M851A, V852A

M. Cecchini

AMP

0568

GST,
RBLP

R467E, K548E,
Y756W, M851A,
V852A

M. Cecchini

AMP

0618

pScodonGSTRBLPGSL

GST,
RBLP

R467E, K548E,
I753A, N757A,
M761A, M851A,
V852A

M. Thwaites

AMP

0735

pCMV-β-Gal

β-Gal

N/A

S. Salama

AMP

0042

pCMV-HADP1

DP1

N/A

M. Classon

AMP

0094

CMV-HAE2F1

E2F1

N/A

F. Dick

AMP

0399

pCMV-HAE2F2

E2F2

N/A

J. Lees

AMP

0319

pMJC22
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pCMV-HAE2F3

E2F3

N/A

J. Lees

AMP

0320

CMV-mycCdh1

Cdh1

N/A

N. Dyson

AMP

0520

pFAD102

RB

N/A

F. Dick

AMP

0039

pFAD200

RB

Y756W

M. Cecchini

AMP

0196

pMJC03

RB

R467E, K548E

M. Cecchini

AMP

0562

pFAD139

RB

I753A, N757A,
M761A

F. Dick

AMP

0059

pFAD292

RB

M851A, V852A

F. Dick

AMP

0412

pMJC20

RB

R467E, K548E,
Y756W

M. Cecchini

AMP

0616

pMJC21

RB

R467E, K548E,
M851A, V852A

M. Cecchini

AMP

0617

RB

R467E, K548E,
Y756W, M851A,
V852A

M. Cecchini

AMP

0618

CMV-RBGSL

RB

R467E, K548E,
I753A, N757A,
M761A, M851A,
V852A

M. Thwaites

AMP

0736

Efla 4F puro

cMyc,
Sox2,
Oct4,
KLF4

N/A

J. Sage

AMP

0737

Tet O 4F

cMyc,
Sox2,
Oct4,
KLF4

N/A

J. Sage

AMP

0738

Tet O Sox2

Sox2

N/A

J. Sage

AMP

0739

Tet O Oct4

Oct4

N/A

J. Sage

AMP

0740

Tet O cMyc

cMyc

N/A

J. Sage

AMP

0741

pMJC22

172

Tet O KLF4

KLF4

N/A

J. Sage

AMP

0742

Gag/pol

Gag/pol

N/A

J. Sage

AMP

0743

Tat

Tat

N/A

J. Sage

AMP

0744

Rev

Rev

N/A

J. Sage

AMP

0745

VSVG

VSVG

N/A

J. Sage

AMP

0746

CMV p107 6x p107

T480R, V490K,
N556E, E560H,
G786T, H797R

S. Rubin

AMP

0747

CMV HASkp2

Skp2

N/A

S. Meloche

AMP

0748

CMV HASkp2 S64A

Skp2

S64A

S. Meloche

AMP

0749

CMV HASkp2 AA

Skp2

S64A, S72A

S. Meloche

AMP

0750

CMV HASkp2 DD

Skp2

S64D, S72D

S. Meloche

AMP

0751

CMV RBGL

RB Large
Pocket

R467E, K548E,
I753A, N757A,
M761A

M. Thwaites

AMP

0752

CMV RBLS

RB Large
Pocket

I753A, N757A,
M761A, M851A,
V852A

M. Thwaites

AMP

0753

pScodon
GST-RBC

RB Large
Pocket

Y756W

M. Thwaites

AMP

0754

pScodon
GST-RBGSC

RB Large
Pocket

R467E, K548E,
M851A, V852A,
Y756W

M. Thwaites

AMP

0755

pScodon
GST-p107 6x

p107

T480R, V490K,
N556E, E560H,
G786T, H797R

S. Rubin

AMP

0756

pScodon
GST-RBC

RB Cterminus

N/A

M. Thwaites

AMP

0757

173

mouse
pet30a HisRBC

RB Cterminus
mouse

N/A

M. Thwaites

KAN

0758
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Appendix C: List of antibodies
Antibody

Protein
recognized

Species

Supplier

CAT. #

Application

p27 (C-19)

p27

Rabbit

Santa Cruz
Biotechnology

Histone H3

Histone H3

Rabbit

abcam

ab70550

WB (1:1000)

SC-69684

WB (1:500)

A2228

WB (1:1000)

SC-528

WB (1:500)

E2F-3
(PG37)

E2F-3

Mouse

Santa Cruz
Biotechnology

β-Actin
(AC-74)

Actin

Mouse

Sigma

347580

FC (1:200),
IF (1:50)

07-631

IP (4µg)

BrdU (B44)

BrdU

Mouse

BD
biosciences

CDK2

CDK2

Rabbit

Millipore

HA (3F10)

HA-Tag

Rat

Sigma

cMyc 9E11

Myc -Tag

Mouse

abcam

ab56

WB (1:10)

pRB G3245

pRB

Mouse

BD
biosciences

554136

WB (1:1000)

CD-20

CD-20

Mouse

BD
biosciences

347673

FC (1:200)

12158167001 WB (1:1000)
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Appendix D: PCR conditions
PCR Conditions Rb1

PCR Conditions Cdkn1b (p27)

Master Mix per reaction
- 1.25 L MgCl2 (50mM)
- 2 L dNTPs (2mM)
- 2 L 10X PCR Buffer (200mM Tris
pH8, 500mM KCl)
- 1L 20M P1-F
- 1L 20M P2-R
- 1L 20M P3
- 9 L Water
- 0.75L Taq (5units/µL)
Total 18L
+ 2L DNA sample

Master Mix per reaction
- 0.5 L MgCl2 (50mM)
- 2 L dNTPs (2mM)
- 2 L 10X PCR Buffer (200mM Tris
pH8, 500mM KCl)
- 1L 20M N1
- 1L 20M K3
- 1L 20M K5
- 10 L Water
- 0.5L Taq (5units/µL)
Total 18L
+ 2L DNA sample

Reaction Conditions
Program - RB1 370bp ST

Reaction Conditions
Program - P27LCM

1.
2.
3.
4.
5.
6.
7.

94C
3:00
94C
0:30
60C
1:00
72C
1:00
Go to Step #2, 34 times
72C
7:00
12C
hold

1.
2.
3.
4.
5.
6.
7.

94C
2:00
94C
0:45
57C
0:45
72C
0:45
Go to Step #2, 34 times
72C
7:00
12C
hold

Expected Results:

Expected Results:

Mutant (Null) = ~470 bp
Heterozygote = 410 bp and ~470 bp
Wild type = 410 bp

Mutant (Null) = 129 bp
Heterozygote = 199 bp and 129 bp
Wild type = 199 bp

Primers
P1: AAT TGC GGC CGC ATC TGC
ATC TTT ATC GC
P2: CCC ATG TTC GGT CCC TAG
P3: GAA GAA CGA CAT CAG CAG

Primers
K3: TGGAACCCTGTGCCATCTCTAT
K5-199:
AGATTGACTATTCATATGCTCTAA
N1-129:
TTGCCAAGTTCTAATTCCATCA
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PCR Conditions Rb1-G

PCR Conditions UBC Cre ERT2

Master Mix per reaction
- 0.5 L MgCl2 (50mM)
- 2 L dNTPs (2mM)
- 2 L 10X PCR Buffer (200mM Tris
pH8, 500mM KCl)
- 1L 20M LoxP-N-F-MC
- 1L 20M LoxP-N-R-MC
- 11 L Water
- 0.5L Taq (5units/µL)
Total 18L
+ 2L DNA sample

Master Mix per reaction
- 0.5 L MgCl2 (50mM)
- 2 L dNTPs (2mM)
- 2 L 10X PCR Buffer (200mM Tris
pH8, 500mM KCl)
- 0.25L 20M Fwd
- 0.25L 20M Rev
- 0.25L 20M Internal Fwd
- 0.25L 20M Internal Rev
- 12 L Water
- 0.5L Taq (5units/µL)
Total 18L
+ 2L DNA sample

Reaction Conditions
Program - NEWRBPRIMERS

Reaction Conditions
Program – SL01

1.
2.
3.
4.
5.
6.
7.

94C
2:00
94C
0:45
55C
0:45
72C
0:45
Go to Step #2, 39 times
72C
5:00
12C
hold

1.
2.
3.
4.
5.
6.
7.

94C
2:30
94C
0:20
60C
0:20
70C
2:00
Go to Step #2, 29 times
72C
10:00
12C
hold

Expected Results:

Expected Results:

Mutant = 280 bp
Heterozygote = 280 bp and 200 bp
Wild type = 200 bp

Positive = 100 bp
Internal Control = 324 bp

Primers
LOXP-N-F-MC:
CAAATTCTCTTCCATTTCCC
LOXP-N-R-MC:
GAATTACAAGTTCAAGACCTAG

Primers
Fwd: GCG GTC TGG CAG TAA AAA
CTA TC
Rev: GTG AAA CAG CAT TGC TGT
CAC TT
Internal Fwd: CTA GGC CAC AGA
ATT GAA AGA TCT
Internal Rev:
GTA GGT GGA AAT TCT AGC ATC
ATC C
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PCR Conditions p53

PCR Conditions Cdkn1a (p21)

Master Mix per reaction
- 1 L MgCl2 (50mM)
- 2.5 L dNTPs (2mM)
- 2.5 L 10X PCR Buffer (200mM Tris
pH8, 500mM KCl)
- 0.62L 20M AM3 primer
- 0.62L 20M AM4 primer
- 0.27L 20M neo-sense primer
- 0.27L 20M neo-antisense primer
- 11 L Water
- 0.5L Taq (5units/µL)
Total 18L
+ 2L DNA sample

Master Mix per reaction
- 0.5 L MgCl2 (50mM)
- 2 L dNTPs (2mM)
- 2 L 10X PCR Buffer (200mM Tris
pH8, 500mM KCl)
- 1L 20M N1
- 1L 20M K3
- 1L 20M K5
- 10 L Water
- 0.5L Taq (5units/µL)
Total 18L
+ 2L DNA sample

Reaction Conditions
Program – P53 New

Reaction Conditions
Program - P21

1.
2.
3.
4.
5.
6.
7.

94C
2:30
94C
0:30
58C
0:30
72C
1:10
Go to Step #2, 29 times
72C
10:00
12C
hold

1.
2.
3.
4.
5.
6.
7.

94C
2:00
94C
0:45
57C
0:45
72C
0:45
Go to Step #2, 34 times
72C
7:00
12C
hold

Expected Results:

Expected Results:

Mutant (Null) = 424 bp
Heterozygote = 424 bp and 548 bp
Wild type = 548 bp

Mutant (Null) = 700 bp
Heterozygote = 872 bp and 700 bp
Wild type = 872 bp

Primers
AM3: ATAGGTCGGCGGTTCAT
AM4: CCCGAGTATCTGGAAGACAG
Neo-sense:
GGAAGGGACTGGCTGCTATTG
Neo-antisense:
CAATATCACGGGTAGCCAACG

Primers
Wild-type: TGA CGA AGT CAA AGT
TCC ACC
Common: AAG CCT TGA TTC TGA
TGT GGG C
Mutant: GCT ATC AGG ACA TAG
CGT TGG C
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PCR Conditions KrasG12D
Master Mix per reaction
- 0.6 L MgCl2 (50mM)
- 2 L dNTPs (2mM)
- 2 L 10X PCR Buffer (200mM Tris pH8, 500mM KCl)
- 0.5L 20M Primer K1
- 0.5L 20M Primer K2
- 0.5L 20M Primer K3
- 11.4 L Water
- 0.5L Taq (5units/µL)
Total 18L
+ 2L DNA sample
Reaction Conditions
Program - P21
1.
2.
3.
4.
5.
6.
7.

95C
2:00
95C
0:30
61C
0:30
72C
0:45
Go to Step #2, 34 times
72C
10:00
4C hold

Expected Results:
Wild type = 622 bp
LSL cassette = 500 bp
1 Lox (Recombined after Cre = 650 bp
Primers
Wild-type: TGA CGA AGT CAA AGT TCC ACC
Common: AAG CCT TGA TTC TGA TGT GGG C
Mutant: GCT ATC AGG ACA TAG CGT TGG C
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Appendix E: Permission for publication by Molecular and
Cellular Biology
Data presented in chapter 2 is published in the journal of Molecular and Cellular Biology
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Data presented in appendix is published in the journal of Molecular and Cellular Biology
Cecchini, M.J., Thwaites, M.J., Talluri, S., MacDonald, J.I., Passos, D.T., Chong, J.L.,
Cantalupo, P., Stafford, P.M., Saenz-Robles, M.T., Francis, S.M., et al. A retinoblastoma
allele that is mutated at its common E2F interaction site inhibits cell proliferation in genetargeted mice. Mol Cell Biol 34, 2029-2045, doi:10.1128/MCB.01589-13 (2014).
See following page for the permission from Molecular and Cellular Biology
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